diff --git a/.gitignore b/.gitignore
index 4726cb1de50101969829298f834671847a3d3c32..12addb7b6c48166cf40f9c5eac38835f93e78dee 100644
--- a/.gitignore
+++ b/.gitignore
@@ -19,3 +19,4 @@ code/test.bib
code/test file gitignore.txt
src/.DS_Store
vite.config.js.timestamp-1732367750130-6d00136194c2.mjs
+vite.config.js.timestamp-1733161862061-488217339257e.mjs
diff --git a/src/App/Timelines.css b/src/App/Timelines.css
index fe6400a9873dd7d082955dbe3a1b99dc8d2814f4..be1bfba540eadcecd4046f9dfdb2ff2bfd2c0ec8 100644
--- a/src/App/Timelines.css
+++ b/src/App/Timelines.css
@@ -185,7 +185,7 @@ button.tabbutton:nth-child(1), button.tabbutton:nth-child(6){
background-color: var(--igemlightgreen);
}
-.Ethics{
+.Other{
background-color: var(--offblack);
}
diff --git a/src/components/Tabs.tsx b/src/components/Tabs.tsx
index aeabae315d38da7bc3820691a5c213c4a9c8bd2f..cf21a27eb5da1bbcd6c80f167a7a28c387d3ab56 100644
--- a/src/components/Tabs.tsx
+++ b/src/components/Tabs.tsx
@@ -87,7 +87,7 @@ import { stringToSlug } from "../utils";
}
if (data[i].pictureurl_implementation) {
imp_img = <div className="hti-box">
- <img src={data[i].pictureurl_implementation} className="hp-timeline-img hti-right" />
+ <img src={data[i].pictureurl_implementation} className="hp-timeline-img hti-left" />
</div>;
}
if (data[i].pictureurl_aim) {
diff --git a/src/contents/Contribution/Wiki/Wiki-downloads.tsx b/src/contents/Contribution/Wiki/Wiki-downloads.tsx
index 2502e4144133df5bac4df0aa5af16ad34a67b881..3cbad11fab9d3f03b26acfd25065f0316152be6b 100644
--- a/src/contents/Contribution/Wiki/Wiki-downloads.tsx
+++ b/src/contents/Contribution/Wiki/Wiki-downloads.tsx
@@ -1,72 +1,217 @@
import { H4 } from "../../../components/Headings";
-import { PDF } from "../../../components/Pdfs";
+import { TwoLinePDF } from "../../../components/Pdfs";
export function WikiDown(){
return(
<>
<div className="col cycletab" id="flyers" style={{display: "block"}}>
+
<div className='row align-items-center'>
- <H4 text="Our Wiki Helper"/>
- <PDF link='https://static.igem.wiki/teams/5247/pdfs/vokabelliste-wiki.pdf' name="vokabelliste-wiki.pdf"/>
- <H4 text="svgs"/>
- <p>We did not use all of our svgs but since this file format looks so good, we want to offer all our svgs to future iGEMers. Feel free to save, rework and use these svgs.</p>
- <div className="row" style={{maxHeight: "100px", marginBottom: "1rem", marginTop: "1rem"}}>
+ <p>Please note that due to the freezing of the wiki we will not be able to continously update the guide. To obtain the current version, email the current iGEM team Bielefeld (info[at]igem-bielefeld.de) or the Head of Wiki from 2024 (liliana.sanfilippo[at]uni-bielefeld.de). </p>
+ <div className="row">
+ <div className="col">
+ <H4 text="Our Wiki Guide"/>
+ <TwoLinePDF link='https://static.igem.wiki/teams/5247/pdfs/wiki-broschure-v1-2.pdf' name="wiki-broschure-v1-2.pdf" />
+ </div>
+ <div className="col">
+ <H4 text="Our Wiki Helper"/>
+ <TwoLinePDF link='https://static.igem.wiki/teams/5247/pdfs/vokabelliste-wiki.pdf' name="vokabelliste-wiki.pdf" />
+ </div>
+ </div>
+ <H4 text="SVGs"/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/albuterol.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/antibiotics-capsule.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/antibiotics-inhaler-with-capsules.svg"/>
+ </div>
<div className="col">
- <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/albuterol.svg"/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/antibiotics-inhaler.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/hypertonic-saline-triple.svg"/>
+ </div>
+ </div>
+ <br/>
+ <hr/>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/orkambi.svg"/>
</div>
<div className="col">
<img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/dna-strang-schmal-fat.svg"/>
</div>
<div className="col">
- <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/antibiotics-capsule.svg"/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/dna-strang-schmal-fatter.svg"/>
</div>
<div className="col">
- <img style={{maxHeight: "80px"}}src="https://static.igem.wiki/teams/5247/scientific-figures/antibiotics-capsule.svg"/>
+ <img style={{maxHeight: "80px"}}src="https://static.igem.wiki/teams/5247/scientific-figures/trikafta-beide.svg"/>
</div>
<div className="col">
<img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/hypertonic-saline-single.svg"/>
</div>
-
</div>
+ <br/>
<hr/>
- <div className="row" style={{maxHeight: "100px", marginBottom: "1rem", marginTop: "1rem"}}>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
<div className="col">
<img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/cough.svg"/>
</div>
<div className="col">
- <img style={{maxHeight: "80px"}} src=""/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/cold.svg"/>
</div>
<div className="col">
- <img style={{maxHeight: "80px"}} src=""/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/mask.svg"/>
</div>
<div className="col">
- <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/hp-introduction-cycle-our-colors.svg"/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/gibbsreflection.svg"/>
</div>
<div className="col">
<img style={{maxHeight: "80px"}}src="https://static.igem.wiki/teams/5247/scientific-figures/feedbackcycle.svg"/>
</div>
- <hr/>
</div>
- <div className="row" style={{maxHeight: "100px", marginBottom: "1rem", marginTop: "1rem"}}>
+ <br/>
+ <hr/>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
<div className="col">
- <img style={{maxHeight: "80px"}} src=""/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/mendelow-1-aktuell.svg"/>
</div>
<div className="col">
- <img style={{maxHeight: "80px"}} src=""/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/mendelow-2.svg"/>
</div>
<div className="col">
- <img style={{maxHeight: "80px"}} src=""/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/mendelow-3-1.svg"/>
</div>
<div className="col">
- <img style={{maxHeight: "80px"}} src=""/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/mendelow-4.svg"/>
</div>
+ </div>
+ <br/>
+ <hr/>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
<div className="col">
- <img style={{maxHeight: "80px"}} src=""/>
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/first-place.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/second-place.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/third-place.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/box.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/certificate.svg"/>
+ </div>
+ </div>
+ <br/>
+ <hr/>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/kit.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/new-box.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/tickets.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/trophy.svg"/>
+ </div>
+ </div>
+ <br/>
+ <hr/>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/download.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/justice.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/talking-bubbles.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/design/icons/test-tube.svg"/>
</div>
</div>
+ <br/>
<hr/>
- <div className="row" style={{maxHeight: "100px", marginBottom: "1rem", marginTop: "1rem"}}>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/bones.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/brain.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/glands.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/heart.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/largeintestine.svg"/>
+ </div>
+ </div>
+ <br/>
+ <hr/>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/liver.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/lungs.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/nose.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/pancreas.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/pregnancy.svg"/>
+ </div>
+ </div>
+ <br/>
+ <hr/>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/skin.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/stomach.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/diet.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/modulators.svg"/>
+ </div>
+ <div className="col">
+ <img style={{maxHeight: "80px"}} src="https://static.igem.wiki/teams/5247/scientific-figures/mucolytics.svg"/>
+ </div>
+ </div>
+ {/* <br/>
+ <hr/>
+ <br/>
+ <div className="row" style={{maxHeight: "100px", marginBottom: "20px", marginTop: "20px", paddingTop: "20px", paddingBottom: "20px"}}>
<div className="col">
<img style={{maxHeight: "80px"}} src=""/>
</div>
@@ -82,7 +227,7 @@ export function WikiDown(){
<div className="col">
<img style={{maxHeight: "80px"}} src=""/>
</div>
- </div>
+ </div> */}
</div>
</div>
</>
diff --git a/src/contents/Contribution/Wiki/wiki-sources.tsx b/src/contents/Contribution/Wiki/wiki-sources.tsx
index d62c77734cf374ca9df344b74868dd98cf00e53a..a1f868fbf93c84971d0affaa56e6d4860c50a2be 100644
--- a/src/contents/Contribution/Wiki/wiki-sources.tsx
+++ b/src/contents/Contribution/Wiki/wiki-sources.tsx
@@ -16,20 +16,41 @@ export function Sources(){
<li> <a href="https://biologicalicons.com/en">https://biologicalicons.com/en</a> </li>
<li> <a href="https://www.svgrepo.com/">https://www.svgrepo.com/</a> </li>
<li> <a href="https://www.humanbiomedia.org/">https://www.humanbiomedia.org/</a> </li>
+ <li><a href="https://smart.servier.com/">https://smart.servier.com/</a></li>
+ </ul>
+ <ul>
+ <li><a href="https://superdesigner.co/tools/svg-backgrounds">https://superdesigner.co/tools/svg-backgrounds</a></li>
</ul>
</Collapsible>
<Collapsible id="wiki-colors" title="Colours" >
- Need a slightly lighter version of one of your colors or a mix of two colours?
<ul>
- <li><a href="https://www.w3schools.com/colors/colors_mixer.asp"> https://www.w3schools.com/colors/colors_mixer.asp</a></li>
+ <li><a href="https://www.w3schools.com/colors/colors_mixer.asp"> Color Mixer</a></li>
+ <li><a href="https://redketchup.io/color-picker">Image Color Picker</a></li>
+ <li><a href="https://coolors.co/">Color Palette Creator</a></li>
+ <li><a href="https://rgbcolorcode.com/color/converter/"> HEX to RGB and back</a></li>
+ <li><a href="https://cssgradient.io/"> CSS gradient picker</a></li>
</ul>
+ {/* <li><a href=""></a></li> */}
</Collapsible>
- <Collapsible id="wiki-tools" title="Coding Tools">
- Generators
+ <Collapsible id="wiki-tools" title="Coding">
<ul>
- <li><a href="https://www.cssportal.com/">https://www.cssportal.com/</a></li>
+ <li><a href="https://www.cssportal.com/">CSS resources</a></li>
+ <ul>
+ <li><a href="https://www.cssportal.com/scss-to-css/">SCSS to CSS</a></li>
+ <li><a href=" https://www.cssportal.com/css-clip-path-generator/">CSS Clip Path generator</a></li>
+ </ul>
+ <li><a href="https://css-tricks.com/snippets/css/a-guide-to-flexbox/">CSS flexbox guide</a></li>
+ <li><a href="https://transform.tools/html-to-jsx">HTML to JSX</a></li>
+ <li><a href="https://nikitahl.github.io/svg-2-code/">Turn SVGs into HTML code</a></li>
+ <li><a href="https://www.svgviewer.dev/svg-to-react-jsx">Turn SVGs into JSX code</a></li>
+ <li><a href="https://www.prettifycss.com/">Prettify CSS</a></li>
<li><a href="https://htmlcss.tools/">https://htmlcss.tools/</a></li>
+ <li><a href="https://beautifytools.com/javascript-beautifier.php">Prettify JS</a></li>
+ <li><a href="https://tympanus.net/Development/ClickEffects/">Click effects</a></li>
+ <li><a href="https://michalsnik.github.io/aos/">AOS</a></li>
+ <li><a href="https://flamingtempura.github.io/bibtex-tidy">Tidy bibtex</a></li>
+ <li><a href="https://www.toptal.com/designers/htmlarrows/arrows/">HTML entity codes</a></li>
</ul>
</Collapsible>
@@ -39,11 +60,6 @@ export function Sources(){
</ul>
</Collapsible>
- <Collapsible id="wiki-svgs" title="SVGs">
- <ul>
- <li><a href="https://superdesigner.co/tools/svg-backgrounds">https://superdesigner.co/tools/svg-backgrounds</a></li>
- </ul>
- </Collapsible>
<Collapsible id="wiki-accessibility" title="Accessibility">
<ul>
diff --git a/src/contents/Contribution/Wiki/wiki-tabs.tsx b/src/contents/Contribution/Wiki/wiki-tabs.tsx
index f02530db8c9523f38c0121e35ca8daef0c272898..9197fe4dc99ef7df5d3292f72cad2c5734bf9016 100644
--- a/src/contents/Contribution/Wiki/wiki-tabs.tsx
+++ b/src/contents/Contribution/Wiki/wiki-tabs.tsx
@@ -1,10 +1,7 @@
import { TabContext, TabList, TabPanel } from "@mui/lab";
import { Box, Tab } from "@mui/material";
import React from "react";
-import { Started } from "./wiki-start";
import { Sources } from "./wiki-sources";
-import { Troubleshooting } from "./troubleshooting";
-import { WikiOverview } from "./wiki-overview";
import { WikiDown } from "./Wiki-downloads";
export function WikiTabs() {
@@ -19,21 +16,15 @@ export function WikiTabs() {
<TabContext value={value}>
<Box sx={{ borderBottom: 1, borderColor: 'divider' }}>
<TabList onChange={handleChange} aria-label="lab API tabs example">
- <Tab label="Overview" value="1" />
- <Tab label="Getting started" value="6" />
- <Tab label="Troubleshooting" value="2" />
- <Tab label="Components" value="3" />
- <Tab label="Downloads" value="4" />
- <Tab label="Resources" value="5" />
+
+ <Tab label="Wiki Guide & Downloads" value="1" />
+ <Tab label="Other Resources" value="2" />
</TabList>
</Box>
- <TabPanel value="1"> <WikiOverview/> </TabPanel>
- <TabPanel value="6"> <Started/> </TabPanel>
- <TabPanel value="2"> <Troubleshooting/> </TabPanel>
- <TabPanel value="3"> </TabPanel>
- <TabPanel value="4"> <WikiDown/> </TabPanel>
- <TabPanel value="5"> <Sources/> </TabPanel>
+
+ <TabPanel value="1"> <WikiDown/> </TabPanel>
+ <TabPanel value="2"> <Sources/> </TabPanel>
</TabContext>
</Box>
);
diff --git a/src/contents/Human Practices/Further Engagement/Entrepreneurship.tsx b/src/contents/Human Practices/Further Engagement/Entrepreneurship.tsx
index 748350a89c18c3dabe33d5730b93bae232801478..0e93fc15fa754764eb10e036564676ad1633217a 100644
--- a/src/contents/Human Practices/Further Engagement/Entrepreneurship.tsx
+++ b/src/contents/Human Practices/Further Engagement/Entrepreneurship.tsx
@@ -1,5 +1,7 @@
import { ButtonOneWithScroll } from "../../../components/Buttons";
import { H4, H5 } from "../../../components/Headings";
+import { TabScrollLink } from "../../../components/Link";
+import EntrepreneurSources from "../../../sources/entre-sources";
import { useTabNavigation } from "../../../utils/TabNavigation";
@@ -173,29 +175,29 @@ export function HPEntrepreneur(){
<H5 text="1. Target Market Definition "/>
<p><b>Patient Population:</b> Cystic Fibrosis (CF) is a rare genetic disorder affecting over 80,000 individuals worldwide, with a significant
concentration in North America and Europe. About 90% of CF patients have at least one copy of the F508del mutation, which makes them potential
- candidates for therapies targeting this mutation [1] [2]. </p>
+ candidates for therapies targeting this mutation. </p>
<p><b>Geographical Focus:</b>The largest markets are in North America and Europe, where CF prevalence is highest, and access to advanced therapies
- like RNA-based treatments is well-supported. This would be the primary focus for our therapy, particularly in countries with established CF
- treatment infrastructures such as the U.S., Germany, and the U.K. [3].</p>
+ like RNA-based treatments is well-supported<TabScrollLink tab="ent-next" scrollId="ent-refs" num="1"/>.This would be the primary focus for our therapy, particularly in countries with established CF
+ treatment infrastructures such as the U.S., Germany, and the U.K.</p>
<p><b>Unmet Needs: </b>Despite advancements like CFTR modulators (e.g., Kaftrio), around 10% of patients do not respond to current treatments and rely on
- symptomatic care [4]. Our RNA-based gene therapy could address this unmet need, specifically targeting the Delta F508 mutation for which many patients have
+ symptomatic care<TabScrollLink tab="ent-next" scrollId="ent-refs" num="2"/>. Our RNA-based gene therapy could address this unmet need, specifically targeting the Delta F508 mutation for which many patients have
limited options. </p>
<H5 text="Market Size and Growth Potential"/>
<p><b>Market Size: </b> The global Cystic Fibrosis treatment market was valued at USD 9.41 billion in 2023 and is expected to grow to USD 29.19 billion by
- 2032, with a compound annual growth rate (CAGR) of 13.4% [5]. This growth is driven by advancements in gene therapy and increased research funding. Gene
- therapy targeting the F508del mutation, the most common CF mutation, presents a significant market opportunity within this larger CF treatment market[6]. </p>
+ 2032, with a compound annual growth rate (CAGR) of 13.4%<TabScrollLink tab="ent-next" scrollId="ent-refs" num="3"/>. This growth is driven by advancements in gene therapy and increased research funding. Gene
+ therapy targeting the F508del mutation, the most common CF mutation, presents a significant market opportunity within this larger CF treatment market. </p>
<p><b>Growth Drivers:</b> The increase in CF patient lifespan due to improved treatments, alongside ongoing innovation in RNA-based therapies, offers
- significant growth potential. The rise in government-backed initiatives and non-profit funding further supports market expansion [7][8]. </p>
+ significant growth potential. The rise in government-backed initiatives and non-profit funding further supports market expansion. </p>
<p><b>Opportunity for RNA-Based Therapies:</b> While current treatments like CFTR modulators provide relief for many patients, approximately 10% of CF
- patients do not benefit from these therapies [9]. Our RNA-based therapy has the potential to capture this segment of the market, addressing an unmet
+ patients do not benefit from these therapies<TabScrollLink tab="ent-next" scrollId="ent-refs" num="2"/>. Our RNA-based therapy has the potential to capture this segment of the market, addressing an unmet
clinical need.</p>
<H5 text="3. Competitive Landscape "/>
<p><b>Current Competitors:</b>The Cystic Fibrosis treatment space is dominated by pharmaceutical giants such as Vertex Pharmaceuticals, which has developed
- CFTR modulators like Kaftrio/Trikafta. These modulators are currently the gold standard for treating CF patients with the F508del mutation [10].
- Other key players in the market include Novartis, Gilead Sciences, and AbbVie, all of whom are active in CF drug development[11].</p>
+ CFTR modulators like Kaftrio/Trikafta. These modulators are currently the gold standard for treating CF patients with the F508del mutation.
+ Other key players in the market include Novartis, Gilead Sciences, and AbbVie, all of whom are active in CF drug development.</p>
<p><b>Gene Therapy Competitors:</b>While CFTR modulators have been highly successful, several companies are exploring gene therapies aimed at addressing the
root cause of CF by correcting or replacing defective CFTR genes. Early-stage gene therapy trials have faced challenges, but advancements in delivery
- technologies and CRISPR-based therapies are opening new pathways[12].</p>
+ technologies and CRISPR-based therapies are opening new pathways<TabScrollLink tab="ent-next" scrollId="ent-refs" num="4"/>.</p>
<p><b>Our Differentiation: </b> Unlike existing CFTR modulators that require lifelong administration, our RNA-based therapy aims to provide a more
permanent solution by directly addressing the genetic cause of CF, specifically targeting patients who do not respond to current CFTR modulators.
This could position us as a unique player in the market, targeting an underserved patient group.</p>
@@ -203,31 +205,33 @@ export function HPEntrepreneur(){
<p><b>Regulatory Hurdles:</b>One of the biggest challenges in bringing a gene therapy to market is navigating the complex regulatory environment.
Compliance with Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) is essential for obtaining approvals from bodies like the FDA and EMA.
Securing approval for RNA-based gene therapies, particularly those targeting rare diseases like Cystic Fibrosis, can involve lengthy and expensive clinical
- trials[13][14].</p>
+ trials.</p>
<p><b>High R&D Costs:</b> Developing gene therapies involves significant upfront costs, from research and development to clinical trials. For a small
biotech startup, securing the necessary funding can be a barrier, especially when competing against established pharmaceutical companies with larger R&D
- budgets[15].</p>
+ budgets.</p>
<p><b>Delivery Challenges:</b> Effective delivery of RNA-based therapies to the lungs remains a technical barrier. While lipid nanoparticles (LNPs) show
promise, optimizing the delivery method to ensure consistent, safe, and effective distribution of the therapy in lung tissues is a challenge that still
- needs to be fully addressed [16].</p>
+ needs to be fully addressed.</p>
<p><b>Market Saturation and Entrenched Competitors:</b> The CF treatment market is already dominated by established players like Vertex Pharmaceuticals.
Gaining a foothold in a market where CFTR modulators are the standard of care will require demonstrating significant clinical advantages, particularly for
- patients not served by existing treatments[17].</p>
+ patients not served by existing treatments.</p>
<H5 text="5. Go-to-Market Strategy"/>
<p><b>Initial Focus on Clinical Partnerships:</b> The first step in bringing our RNA-based gene therapy to market will be partnering with academic
institutions and clinical research centers to conduct initial clinical trials. Establishing credibility through collaborations with key opinion leaders
- in Cystic Fibrosis treatment will help build trust and validate the efficacy of our therapy [18][19].</p>
+ in Cystic Fibrosis treatment will help build trust and validate the efficacy of our therapy.</p>
<p><b>Early Adopters: </b>Our focus will be on targeting early adopters, such as specialized Cystic Fibrosis clinics and hospitals that are familiar
with cutting-edge gene therapies. These institutions are more likely to adopt novel treatments and provide us with real-world data to further refine our
- therapy[20].</p>
+ therapy.</p>
<p><b>Partnerships with Biotech and Pharmaceutical Companies:</b> Partnering with established biotech or pharmaceutical companies could help accelerate
commercialization by providing access to distribution channels, regulatory expertise, and additional funding. Licensing agreements or co-development
- deals with companies specializing in gene therapy could be key to scaling production[21].</p>
+ deals with companies specializing in gene therapy could be key to scaling production.</p>
<p><b>Regulatory Strategy:</b>Navigating the regulatory environment will be a priority, and early engagement with the FDA, EMA, and other regulatory
bodies will help ensure a smoother approval process. Focusing on orphan drug designation or fast-track approvals for rare diseases like Cystic Fibrosis
- could expedite the regulatory timeline[22].</p>
+ could expedite the regulatory timeline.</p>
<p><b>Long-Term Vision:</b> After initial success in treating Cystic Fibrosis, our RNA-based therapy could be expanded to treat other genetic disorders.
- The modular nature of our technology allows us to adapt the therapy for other rare diseases, providing a broader market potential in the future[23].</p>
+ The modular nature of our technology allows us to adapt the therapy for other rare diseases, providing a broader market potential in the future.</p>
+ <H5 id="ent-refs" text="References" ></H5>
+ <EntrepreneurSources/>
</div>
</div>
diff --git a/src/contents/Human Practices/IHP.tsx b/src/contents/Human Practices/IHP.tsx
index a1d0c4bb693270125e75067332e510e33dab4554..cd0d4dfaa8720cc7f13149c18498241f9968caa1 100644
--- a/src/contents/Human Practices/IHP.tsx
+++ b/src/contents/Human Practices/IHP.tsx
@@ -230,30 +230,30 @@ export function HPIntegrated(){
<div className="row align-items-center">
<div className="col ">
- <ButtonOne text="Patients" open="pats" openclass="subcycletab"></ButtonOne>
+ <ButtonOne text="Patients" open="swot&subTab=pats" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
- <ButtonOne text="Industry" open="inds" openclass="subcycletab"></ButtonOne>
+ <ButtonOne text="Industry" open="swot&subTab=inds" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
- <ButtonOne text="Academia" open="acs" openclass="subcycletab"></ButtonOne>
+ <ButtonOne text="Academia" open="swot&subTab=acs" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
- <ButtonOne text="Healthcare" open="healths" openclass="subcycletab"></ButtonOne>
+ <ButtonOne text="Healthcare" open="swot&subTab=healths" openclass="subcycletab"></ButtonOne>
</div>
</div>
<div className="row align-items-center">
< div className="col ">
- <ButtonOne text="Government" open="govs" openclass="subcycletab"></ButtonOne>
+ <ButtonOne text="Government" open="swot&subTab=govs" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
- <ButtonOne text="Community" open="comms" openclass="subcycletab"></ButtonOne>
+ <ButtonOne text="Community" open="swot&subTab=comms" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
- <ButtonOne text="The Public" open="pubs" openclass="subcycletab"></ButtonOne>
+ <ButtonOne text="The Public" open="swot&subTab=pubs" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
- <ButtonOne text="Business" open="busi" openclass="subcycletab"></ButtonOne>
+ <ButtonOne text="Business" open="swot&subTab=busi" openclass="subcycletab"></ButtonOne>
</div>
</div>
<div className="col subcycletab" id="pats" style={{display: "block"}}>
@@ -294,450 +294,412 @@ export function HPIntegrated(){
</div>
<div className="col subcycletab" id="inds" style={{display: "none"}}>
<H5 text="Pharmaceutical Companies" />
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Resources for large-scale production and distribution </td>
- <td>Experience with regulatory processes </td>
- <td>Strong research and development capabilities </td>
- </tr>
- <tr>
- <td>Focus on profitability may conflict with patient affordability </td>
- <td>Long development timelines </td>
- <td>Potential for high pricing </td>
- </tr>
- <tr>
- <td>Potential for developing new treatment modalities </td>
- <td>Market expansion and competitive advantage </td>
- <td>Partnerships with research institutions </td>
- </tr>
- <tr>
- <td>High cost and risk associated with new therapy development </td>
- <td>Stringent regulatory and compliance requirements </td>
- <td>Potential public backlash over high treatment costs </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Resources for large-scale production and distribution</td>
+ <td>Focus on profitability may conflict with patient affordability</td>
+ <td>Potential for developing new treatment modalities</td>
+ <td>High cost and risk associated with new therapy development</td>
+ </tr>
+ <tr>
+ <td>Experience with regulatory processes</td>
+ <td>Long development timelines</td>
+ <td>Market expansion and competitive advantage</td>
+ <td>Stringent regulatory and compliance requirements</td>
+ </tr>
+ <tr>
+ <td>Strong research and development capabilities</td>
+ <td>Potential for high pricing</td>
+ <td>Partnerships with research institutions</td>
+ <td>Potential public backlash over high treatment costs</td>
+ </tr>
+ </tbody>
+</table>
+
<H5 text="Bioengineering and Biotechnology Departments "/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Agile and innovative, can quickly adapt to new technologies </td>
- <td>Focused on niche markets and cutting-edge solutions </td>
- <td>Strong entrepreneurial spirit </td>
- </tr>
- <tr>
- <td></td>
- <td></td>
- <td></td>
- </tr>
- <tr>
- <td>Opportunity for rapid growth and partnership with larger firms </td>
- <td>Potential to disrupt existing markets with innovative solutions </td>
- <td>Opportunities for collaboration and acquisition </td>
- </tr>
- <tr>
- <td>High risk of failure and market volatility </td>
- <td>Intense competition and fast-paced industry changes </td>
- <td>Regulatory and market entry barriers </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Agile and innovative, can quickly adapt to new technologies</td>
+ <td>Focused on niche markets and cutting-edge solutions</td>
+ <td>Opportunity for rapid growth and partnership with larger firms</td>
+ <td>High risk of failure and market volatility</td>
+ </tr>
+ <tr>
+ <td>Strong entrepreneurial spirit</td>
+ <td></td>
+ <td>Potential to disrupt existing markets with innovative solutions</td>
+ <td>Intense competition and fast-paced industry changes</td>
+ </tr>
+ <tr>
+ <td></td>
+ <td></td>
+ <td>Opportunities for collaboration and acquisition</td>
+ <td>Regulatory and market entry barriers</td>
+ </tr>
+ </tbody>
+</table>
+
</div>
<div className="col subcycletab" id="acs" style={{display: "none"}}>
<H5 text="Genetic Research Institutions "/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Expertise in genetic disorders and advanced research capabilities </td>
- <td>Access to state-of-the-art research facilities </td>
- <td>Strong track record of innovation </td>
- </tr>
- <tr>
- <td>May have limited practical experience with therapy delivery </td>
- <td>Potential disconnect between research and clinical application </td>
- <td>High operational costs </td>
- </tr>
- <tr>
- <td>Collaboration can lead to breakthroughs in gene editing </td>
- <td>Potential for groundbreaking research and new discoveries </td>
- <td>Collaborative research opportunities </td>
- </tr>
- <tr>
- <td>High competition for funding and research grants </td>
- <td>Rapid technological changes requiring constant adaptation </td>
- <td>Ethical and regulatory challenges </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Expertise in genetic disorders and advanced research capabilities</td>
+ <td>May have limited practical experience with therapy delivery</td>
+ <td>Collaboration can lead to breakthroughs in gene editing</td>
+ <td>High competition for funding and research grants</td>
+ </tr>
+ <tr>
+ <td>Access to state-of-the-art research facilities</td>
+ <td>Potential disconnect between research and clinical application</td>
+ <td>Potential for groundbreaking research and new discoveries</td>
+ <td>Rapid technological changes requiring constant adaptation</td>
+ </tr>
+ <tr>
+ <td>Strong track record of innovation</td>
+ <td>High operational costs</td>
+ <td>Collaborative research opportunities</td>
+ <td>Ethical and regulatory challenges</td>
+ </tr>
+ </tbody>
+</table>
+
<H5 text="Universities and Academic Researchers "/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Strong research foundation and innovation capabilities </td>
- <td>Access to a diverse pool of academic talent </td>
- <td>Established research infrastructure </td>
- </tr>
- <tr>
- <td>May have limited resources for commercialization </td>
- <td>Limited industry connections </td>
- <td>High competition for academic grants </td>
- </tr>
- <tr>
- <td>Potential for groundbreaking research and new discoveries </td>
- <td>Collaboration with industry for applied research </td>
- <td>Opportunities for interdisciplinary research </td>
- </tr>
- <tr>
- <td>Funding limitations and bureaucratic challenges </td>
- <td>Intellectual property and technology transfer issues </td>
- <td>Balancing academic research with practical applications </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Strong research foundation and innovation capabilities</td>
+ <td>May have limited resources for commercialization</td>
+ <td>Established research infrastructure</td>
+ <td>Funding limitations and bureaucratic challenges</td>
+ </tr>
+ <tr>
+ <td>Access to a diverse pool of academic talent</td>
+ <td>Limited industry connections</td>
+ <td>High competition for academic grants</td>
+ <td>Intellectual property and technology transfer issues</td>
+ </tr>
+ <tr>
+ <td>Potential for groundbreaking research and new discoveries</td>
+ <td>Collaboration with industry for applied research</td>
+ <td>Opportunities for interdisciplinary research</td>
+ <td>Balancing academic research with practical applications</td>
+ </tr>
+ </tbody>
+</table>
+
</div>
<div className="col subcycletab" id="healths" style={{display: "none"}}>
<H5 text="Pulmonologists and Respiratory Specialists"/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Deep understanding of CF and its complications </td>
- <td>Direct patient care experience </td>
- <td>Established patient trust and rapport </td>
- </tr>
- <tr>
- <td>May lack expertise in gene editing and new delivery systems </td>
- <td>Limited time and resources for research involvement </td>
- <td>Risk of slow adoption of new technologies </td>
- </tr>
- <tr>
- <td>Can provide valuable insights for therapy optimization </td>
- <td>Opportunities for clinical trials and patient feedback </td>
- <td>Enhanced treatment protocols through collaboration </td>
- </tr>
- <tr>
- <td>Resistance to adopt new and unproven therapies </td>
- <td>Potential liability issues with new treatments </td>
- <td>Competition from alternative therapies </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Deep understanding of CF and its complications</td>
+ <td>May lack expertise in gene editing and new delivery systems</td>
+ <td>Can provide valuable insights for therapy optimization</td>
+ <td>Resistance to adopt new and unproven therapies</td>
+ </tr>
+ <tr>
+ <td>Direct patient care experience</td>
+ <td>Limited time and resources for research involvement</td>
+ <td>Opportunities for clinical trials and patient feedback</td>
+ <td>Potential liability issues with new treatments</td>
+ </tr>
+ <tr>
+ <td>Established patient trust and rapport</td>
+ <td>Risk of slow adoption of new technologies</td>
+ <td>Enhanced treatment protocols through collaboration</td>
+ <td>Competition from alternative therapies</td>
+ </tr>
+ </tbody>
+</table>
+
+
+
<H5 text="Specialized Clinics and Hospitals"/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Direct access to patient population </td>
- <td>Ability to conduct clinical trials </td>
- <td>Experienced medical staff and infrastructure </td>
- </tr>
- <tr>
- <td>May lack expertise in gene therapy and new delivery systems </td>
- <td>High operational costs </td>
- <td>Potential liability and ethical concerns </td>
- </tr>
- <tr>
- <td>Clinical trials and real-world application of new therapies </td>
- <td>Opportunities for improving patient care and outcomes </td>
- <td>Collaboration with research institutions for therapy development </td>
- </tr>
- <tr>
- <td>High cost and complexity of integrating new therapies </td>
- <td>Resistance from clinical staff to adopt new technologies </td>
- <td>Competition for patients and clinical trial participation </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Direct access to patient population</td>
+ <td>May lack expertise in gene therapy and new delivery systems</td>
+ <td>Clinical trials and real-world application of new therapies</td>
+ <td>High cost and complexity of integrating new therapies</td>
+ </tr>
+ <tr>
+ <td>Ability to conduct clinical trials</td>
+ <td>High operational costs</td>
+ <td>Opportunities for improving patient care and outcomes</td>
+ <td>Resistance from clinical staff to adopt new technologies</td>
+ </tr>
+ <tr>
+ <td>Experienced medical staff and infrastructure</td>
+ <td>Potential liability and ethical concerns</td>
+ <td>Collaboration with research institutions for therapy development</td>
+ <td>Competition for patients and clinical trial participation</td>
+ </tr>
+ </tbody>
+</table>
+
+
+
<H5 text="Healthcare Networks"/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Broad reach and influence </td>
- <td>Ability to implement new therapies widely </td>
- <td>Established relationships with patient communities </td>
- </tr>
- <tr>
- <td>Variability in network capabilities and resources </td>
- <td>Complex coordination required </td>
- <td>Potential disparities in care quality </td>
- </tr>
- <tr>
- <td>Potential for large-scale impact on patient care </td>
- <td>Leveraging network for large-scale clinical trials </td>
- <td>Standardizing care across multiple facilities </td>
- </tr>
- <tr>
- <td>Organizational resistance to change </td>
- <td>Economic pressures and budget constraints </td>
- <td>Variability in regulatory compliance across regions </td>
- </tr>
- </tbody>
- </table>
- <H5 text=""/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td></td>
- <td></td>
- <td></td>
- </tr>
- <tr>
- <td></td>
- <td></td>
- <td></td>
- </tr>
- <tr>
- <td></td>
- <td></td>
- <td></td>
- </tr>
- <tr>
- <td></td>
- <td></td>
- <td></td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Broad reach and influence</td>
+ <td>Variability in network capabilities and resources</td>
+ <td>Established relationships with patient communities</td>
+ <td>Organizational resistance to change</td>
+ </tr>
+ <tr>
+ <td>Potential for large-scale impact on patient care</td>
+ <td>Ability to implement new therapies widely</td>
+ <td>Standardizing care across multiple facilities</td>
+ <td>Economic pressures and budget constraints</td>
+ </tr>
+ <tr>
+ <td>Leveraging network for large-scale clinical trials</td>
+ <td>Complex coordination required</td>
+ <td>Potential disparities in care quality</td>
+ <td>Variability in regulatory compliance across regions</td>
+ </tr>
+ </tbody>
+</table>
+
</div>
<div className="col subcycletab" id="govs" style={{display: "none"}}>
<H5 text="Bioethics Committees "/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Ensure ethical standards are met </td>
- <td>Provide guidance on complex issues </td>
- <td>Enhance credibility and acceptance of new therapies </td>
- </tr>
- <tr>
- <td>May be conservative and slow to approve new technologies </td>
- <td>Potential for conflicting opinions within the committee </td>
- <td>Limited authority to enforce decisions </td>
- </tr>
- <tr>
- <td>Establishing ethical frameworks for new therapies </td>
- <td>Enhancing public trust through ethical oversight </td>
- <td>Collaboration with regulatory agencies for comprehensive oversight </td>
- </tr>
- <tr>
- <td>Ethical dilemmas and public perception issues </td>
- <td>Rapid advancements outpacing ethical guidelines </td>
- <td>Misalignment with fast-paced technological advancements </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Ensure ethical standards are met</td>
+ <td>May be conservative and slow to approve new technologies</td>
+ <td>Establishing ethical frameworks for new therapies</td>
+ <td>Ethical dilemmas and public perception issues</td>
+ </tr>
+ <tr>
+ <td>Provide guidance on complex issues</td>
+ <td>Potential for conflicting opinions within the committee</td>
+ <td>Enhancing public trust through ethical oversight</td>
+ <td>Rapid advancements outpacing ethical guidelines</td>
+ </tr>
+ <tr>
+ <td>Enhance credibility and acceptance of new therapies</td>
+ <td>Limited authority to enforce decisions</td>
+ <td>Collaboration with regulatory agencies for comprehensive oversight</td>
+ <td>Misalignment with fast-paced technological advancements</td>
+ </tr>
+ </tbody>
+</table>
+
+
+
+
<H5 text="Legal Experts"/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Navigate complex legal landscapes </td>
- <td>Ensure compliance with regulations </td>
- <td>Expertise in healthcare law and genetic research regulations </td>
- </tr>
- <tr>
- <td>High costs for legal services </td>
- <td>Potential for lengthy legal processes </td>
- <td>Risk of stifling innovation with overly cautious advice </td>
- </tr>
- <tr>
- <td>Development of comprehensive legal frameworks for new therapies </td>
- <td>Protecting intellectual property and ensuring regulatory compliance </td>
- <td>Advising on best practices for ethical and legal standards </td>
- </tr>
- <tr>
- <td>Legal challenges and liability issues </td>
- <td>Rapidly changing legal environments and regulations </td>
- <td>Potential for litigation and legal disputes </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Navigate complex legal landscapes</td>
+ <td>High costs for legal services</td>
+ <td>Development of comprehensive legal frameworks for new therapies</td>
+ <td>Legal challenges and liability issues</td>
+ </tr>
+ <tr>
+ <td>Ensure compliance with regulations</td>
+ <td>Potential for lengthy legal processes</td>
+ <td>Protecting intellectual property and ensuring regulatory compliance</td>
+ <td>Rapidly changing legal environments and regulations</td>
+ </tr>
+ <tr>
+ <td>Expertise in healthcare law and genetic research regulations</td>
+ <td>Risk of stifling innovation with overly cautious advice</td>
+ <td>Advising on best practices for ethical and legal standards</td>
+ <td>Potential for litigation and legal disputes</td>
+ </tr>
+ </tbody>
+</table>
+
</div>
<div className="col subcycletab" id="comms" style={{display: "none"}}>
<H5 text="Patient and Community Outreach Programs"/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Increase awareness and education </td>
- <td>Build public support </td>
- <td>Foster connections between patients, researchers, and healthcare providers </td>
- </tr>
- <tr>
- <td>Limited reach and resources </td>
- <td>Potential misinformation </td>
- <td>Dependence on volunteer efforts </td>
- </tr>
- <tr>
- <td>Enhanced public engagement and support for new therapies </td>
- <td>Opportunities for community-driven advocacy </td>
- <td>Raising funds and resources through public engagement </td>
- </tr>
- <tr>
- <td>Public skepticism and resistance to new technologies </td>
- <td>Competing messages and priorities among various community groups </td>
- <td>Miscommunication leading to misinformation </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Increase awareness and education</td>
+ <td>Limited reach and resources</td>
+ <td>Foster connections between patients, researchers, and healthcare providers</td>
+ <td>Public skepticism and resistance to new technologies</td>
+ </tr>
+ <tr>
+ <td>Build public support</td>
+ <td>Potential misinformation</td>
+ <td>Dependence on volunteer efforts</td>
+ <td>Competing messages and priorities among various community groups</td>
+ </tr>
+ <tr>
+ <td>Enhanced public engagement and support for new therapies</td>
+ <td>Opportunities for community-driven advocacy</td>
+ <td>Raising funds and resources through public engagement</td>
+ <td>Miscommunication leading to misinformation</td>
+ </tr>
+ </tbody>
+</table>
+
</div>
<div className="col subcycletab" id="pubs" style={{display: "none"}}>
<H5 text="Educational Institutions"/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Educate future scientists and healthcare professionals </td>
- <td>Promote research and innovation </td>
- <td>Established infrastructure for education and research </td>
- </tr>
- <tr>
- <td>Limited funding and resources for large-scale projects </td>
- <td>Potential for academic bureaucracy </td>
- <td>High competition for research grants </td>
- </tr>
- <tr>
- <td>Opportunity to foster new talent and innovation </td>
- <td>Collaboration with industry and research institutions </td>
- <td>Opportunities for interdisciplinary education and research </td>
- </tr>
- <tr>
- <td>Funding constraints and academic pressures </td>
- <td>Balancing academic objectives with practical applications </td>
- <td>Risk of brain drain to more lucrative industries </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Educate future scientists and healthcare professionals</td>
+ <td>Limited funding and resources for large-scale projects</td>
+ <td>Opportunity to foster new talent and innovation</td>
+ <td>Funding constraints and academic pressures</td>
+ </tr>
+ <tr>
+ <td>Promote research and innovation</td>
+ <td>Potential for academic bureaucracy</td>
+ <td>Collaboration with industry and research institutions</td>
+ <td>Balancing academic objectives with practical applications</td>
+ </tr>
+ <tr>
+ <td>Established infrastructure for education and research</td>
+ <td>High competition for research grants</td>
+ <td>Opportunities for interdisciplinary education and research</td>
+ <td>Risk of brain drain to more lucrative industries</td>
+ </tr>
+ </tbody>
+</table>
+
</div>
<div className="col subcycletab" id="busi" style={{display: "none"}}>
<H5 text="Funding Agencies and Venture Capitalists"/>
- <table cellPadding={10} cellSpacing={0} >
- <thead>
- <tr>
- <th>Strengths</th>
- <th>Weaknesses</th>
- <th>Opportunities</th>
- <th>Threats</th>
- </tr>
- </thead>
- <tbody>
- <tr>
- <td>Provide crucial financial support </td>
- <td>Drive innovation through investment </td>
- <td>Extensive networks and industry connections </td>
- </tr>
- <tr>
- <td>Focus on ROI may limit funding for high-risk projects </td>
- <td>High competition for funding </td>
- <td>Risk aversion may limit innovative but uncertain projects </td>
- </tr>
- <tr>
- <td>Potential for high returns and impact on healthcare </td>
- <td>Supporting transformative technologies </td>
- <td>Identifying and nurturing breakthrough technologies </td>
- </tr>
- <tr>
- <td>Economic downturns affecting investment capacity </td>
- <td>Potential for high financial losses </td>
- <td>Changes in economic and policy environments </td>
- </tr>
- </tbody>
- </table>
+ <table cellPadding={10} cellSpacing={0}>
+ <thead>
+ <tr>
+ <th>Strengths</th>
+ <th>Weaknesses</th>
+ <th>Opportunities</th>
+ <th>Threats</th>
+ </tr>
+ </thead>
+ <tbody>
+ <tr>
+ <td>Provide crucial financial support</td>
+ <td>Focus on ROI may limit funding for high-risk projects</td>
+ <td>Extensive networks and industry connections</td>
+ <td>Economic downturns affecting investment capacity</td>
+ </tr>
+ <tr>
+ <td>Drive innovation through investment</td>
+ <td>High competition for funding</td>
+ <td>Risk aversion may limit innovative but uncertain projects</td>
+ <td>Potential for high financial losses</td>
+ </tr>
+ <tr>
+ <td>Potential for high returns and impact on healthcare</td>
+ <td>Supporting transformative technologies</td>
+ <td>Identifying and nurturing breakthrough technologies</td>
+ <td>Changes in economic and policy environments</td>
+ </tr>
+ </tbody>
+</table>
+
</div>
</div>
<div className="col framecycletab" id="thirdparty" style={{display: "none"}}>
diff --git a/src/contents/description.tsx b/src/contents/description.tsx
index 7d9787a3408c884e46f96f5490abc94ff5c597b6..20e4e240d77993607a6d96c63b1b8c99a9edb390 100644
--- a/src/contents/description.tsx
+++ b/src/contents/description.tsx
@@ -47,7 +47,7 @@ export function Description() {
pic1="https://static.igem.wiki/teams/5247/photos/other/max-bild.webp"
alt1=""
description="Picture from our interview with Max."
- num="1"
+ num="1 "
/>
</div>
</div>
@@ -304,7 +304,7 @@ export function Description() {
<OneFigure
pic1="https://ars.els-cdn.com/content/image/1-s2.0-S1773224724002156-gr3_lrg.jpg"
alt1="Aufnahme LNP"
- num={8}
+ num={7}
description={<span> Endosomal escape vs degradation of LNP cargo at endocytosis <SupScrollLink label="4"/>.</span>}
/>
</div>
@@ -333,7 +333,7 @@ export function Description() {
pic1="https://static.igem.wiki/teams/5247/delivery/big-plan-inhalation-teil-del.webp"
alt1=""
description="Schematic representation our LNP-based drug delivery system."
- num="9"
+ num="8"
/>
</div>
<p>To evaluate the <strong>delivery efficiency</strong>, we transfected HEK293 and CFBE41o- cells using fluorescent cargo and quantified the results through flow cytometry analysis. We also ensured that AirBuddy meets the necessary standards for safety and efficacy since we conducted extensive <a onClick={() => goToPageAndScroll ('In-Depth Characterization of LNPsH', '/materials-methods')}> characterization of the LNPs </a>using physicochemical techniques such as Zeta potential analysis, Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), and Cryogenic Electron Microscopy (cryo-EM). These methods confirmed the stability and optimal size distribution of the nanoparticles. Furthermore, <strong>cytotoxicity assessments</strong> including MTT and proliferation assays demonstrated that our LNPs are biocompatible despite the incorporation of <a onClick={() => goToPageWithTabAndCollapsible({tabId:'tab-delivery', path: '/engineering', collapseId: "Col1"})}>PEG</a> and other ambivalent components. These findings reinforce AirBuddy's potential as a safe and effective tool for pulmonary delivery, with broad implications for gene therapies targeting lung diseases.</p>
@@ -355,7 +355,7 @@ export function Description() {
<p>Ultimately, our vision is to create a therapeutic approach that not only offers a cure that is safe and efficient but also maximizes convenience for the patient. With an easy-to-use inhaler, patients could administer their treatment with minimal disruption to their daily lives, inhaling the gene therapy in just a few breaths, leaving the rest of the process to the science we've built into PreCyse. By reducing the frequency of administration and simplifying the delivery method, we aim to make gene therapy for Cystic Fibrosis both accessible and practical for patients around the world. </p>
<OneFigure
pic1="https://static.igem.wiki/teams/5247/delivery/big-plan-inhalation-del-mech.webp"
- num={10}
+ num={9}
description="Illustration of our path from final product to prime editing in lung epithelial cells."
alt1="Illustration of our path from final product to prime editing in lung epithelial cells."
/>
diff --git a/src/contents/engineering.tsx b/src/contents/engineering.tsx
index f70b1d154a710b9304ce6b31c7c6b1abb6a53522..634c8e249ecd185ddbef57ecdab5ecbafbe750f0 100644
--- a/src/contents/engineering.tsx
+++ b/src/contents/engineering.tsx
@@ -549,7 +549,8 @@ export function Engineering() {
<div className="casettecontainer">
<div className="pegrnabox" style={{height: 'auto', width: '50%'}}>
<img src="https://static.igem.wiki/teams/5247/engineering-cycle/pegrna-overview.svg" alt="Illustration of the key components in our pegRNAs, including spacer, gRNA scaffold, primer binding sequence, reverse transcriptase template, tevopreQ1 3' stem loop motif and templates for main and silent edits."/>
- <figcaption><b>Figure 1: Illustration of the key components in our pegRNAs, including spacer, gRNA scaffold, primer binding sequence (PBS), reverse transcriptase template (RTT), tevopreQ1 3' stem loop motif and templates for main and silent edits.</b> </figcaption>
+ <figcaption><b>Figure 1:</b> Illustration of the key components in our pegRNAs, including spacer, gRNA scaffold, primer binding sequence
+ (PBS), reverse transcriptase template (RTT), tevopreQ1 3' stem loop motif and templates for main and silent edits. </figcaption>
</div>
</div>
diff --git a/src/contents/judging.tsx b/src/contents/judging.tsx
index 40b92a45d72d8ec2971d766528430d7db1050e10..ee3cd9a1baf4a22f42e1d71c18dfc8936c8d624b 100644
--- a/src/contents/judging.tsx
+++ b/src/contents/judging.tsx
@@ -1,3 +1,4 @@
+import { H3, H4 } from "../components/Headings";
import { BlockQuoteB } from "../components/Quotes";
import { Section } from "../components/sections";
import { useNavigation } from "../utils";
@@ -33,8 +34,7 @@ export function Judging() {
</Section>
<div className="row align-items-center">
<div className="col">
- <iframe title="Bielefeld-CeBiTec: Introduction (2024) [English]" width="100%" height="600px" src="https://video.igem.org/videos/embed/9ffc5914-df86-4ba7-a0eb-f324694988ee" frameBorder="0" allowFullScreen={true} sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
-
+ <iframe title="Bielefeld-CeBiTec: Next-Generation Prime Editing as Cystic Fibrosis Gene Therapy (2024) - Team Presentation [English]" width="560" height="315" src="https://video.igem.org/videos/embed/479e7f99-6931-47bc-9193-d4367beba4f2" frameBorder="0" allowFullScreen sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
</div>
</div>
<Section title="Best Therapeutic Project" id="Best Therapeutic Project">
@@ -117,6 +117,99 @@ export function Judging() {
to revolutionize treatment for this life-threatening condition, while our contributions to biosafety and part development will benefit the broader
synthetic biology ecosystem. We are confident that our project is deserving of recognition in multiple award categories, including <b>Best Therapeutic Project</b>, <b>Best Integrated Human Practices</b>, <b>Safety and Security Award</b>, and <b>Best New Basic Part</b>. Through our work, we hope to inspire future iGEM teams to pursue solutions that are both scientifically excellent and socially responsible. </p>
</Section>
+ <Section title="Judging Session" id="Judging Session">
+ <div className="row align-items-center">
+ <div className="col">
+ <iframe title="Bielefeld-CeBiTec: Judging Session (2024)" width="560" height="315" src="https://video.igem.org/videos/embed/d90ef3d2-1bb5-426e-8ab7-8e644d1a22a5" frameBorder="0" allowFullScreen sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
+ </div>
+ </div>
+ <H3 text="Judging Feedback" id="Judging Session1"></H3>
+ <H4 text="Judge 1"></H4>
+ <div className="row feedbackbfh">
+ <div className="col b-lg">
+ <ul>
+ <li>
+ I could see engineering principles and mindsets even in the presentation video. It is a very well-engineered and designed project. Every progress started with some hypotheses. The team tested many hypotheses; many didn’t work but they were able to learn and improve.
+ </li>
+ <li>
+ Documentation is very detailed in general. Specifically, the project description comes with reviews of cystic fibrosis and some basic terms so that anyone with basic molecular biology knowledge would be able to understand the project. The graphics, where there are, also facilitate understanding of technology.
+ </li>
+ <li>
+ The human practices are amazing, significantly influencing key project decisions. They went beyond obvious issues (e.g., how health insurance might cover gene therapies, ethics associated with handling patient-derived cells, biobank), showing compelling evidence that it is responsible and good. The same can be said on the team’s safety work.
+ </li>
+ </ul>
+ </div>
+ <div className="col b-lo">
+ <ul>
+ <li>
+ I don’t see how the proposed new basic part BBa_K5247135 can be useful for the wider community. It is designed with a very specific purpose in mind, of which the characterization is also not done in calibrated units. Basically, one can test different pegRNAs for the F508del mutation in the CFTR gene with fluorescence of the internal positive control arbitrarily set as 100%.
+ </li>
+ <li>
+ I appreciate the extensive documentation of human practices. The way different feedback or research was incorporated is clear but the rationale for the stakeholders chosen is not always clear. It becomes sort of a laundry list of everything that affected the team with too many sections and subtitles.
+ </li>
+ <li>
+ I’m impressed by the fact that the team has access to some sophisticated technology like cryogenic electron microscopy but it’s not clear why these characterizations are necessary, i.e., what the research question is. In fact, the team would then observe various problems associated with these methods. For example, “for SEM analysis, the samples were dried and observed under vacuum, which probably have affected the structure and shape of the LNPs.†If this is the case, then why would the team do it from the beginning?
+ </li>
+ <li>
+ The contributions of the safety work (i.e. primary cultures, biosafety measures, innovative safety mechanisms and regulatory compliance), particularly to what extent they build on existing resources and standards, particularly those from the iGEM community, are not very clear.
+ </li>
+</ul>
+
+ </div>
+ </div>
+
+ <H4 text="Judge 2"></H4>
+ <div className="row feedbackbfh">
+ <div className="col b-lg">
+ <p>I enjoyed browsing through the Wiki, very clear and easy to understand and consume. Commendable demonstration of human practices and good integration of feedback. The Project Presentation is professionally done, enjoyable to watch. I highly encourage the tactic of team members walking around and engaging with judges/other teams. I loved the confidence. Wiki has mobile version, which is well appreciated. </p>
+ </div>
+ <div className="col b-lo">
+ <p>I enjoyed the Calendar feature in Project Documentation, but the dates did not always work. There are still some Lorem Ipsum paragraphs remaining (Results, for instance). Visuals in the Registry part are too big and are not well visible.</p>
+ </div>
+ </div>
+
+ <H4 text="Judge 3"></H4>
+ <div className="row feedbackbfh">
+ <div className="col b-lg">
+ <p>Very well done team Bielefed-CeBiTec. I thought that your project design was very well thought out and was able to clearly see the impact on quality of life that your project would help restore in CF patients. Over the course of this past year, you have done an impressive amount of work, and I think tailoring your project to not only focus on accuracy of your guide RNA but also ensuring the best possible delivery mechanisms to ensure cell uptake was a smart move if you were to track this for market. I also appreciated just how thorough your wiki presents your work, and the amount of effort put into your human practices, engaging with not only members of academia and healthcare, but actual people living with CF. Each page sufficiently attributed and cited original ideas, and the flow from top to bottom of the page made logical sense and made my life as a judge easier. Well done overall, and best of luck as you continue working with this!</p>
+ </div>
+ <div className="col b-lo">
+ <p>There were a couple of notes that stood out to me regarding your wiki and promotional video that I would like to highlight for next year's team. With your individual part designs and part pages, I did not see sufficient data within the part page itself to get excited about the work and how the part can help future iGEMers. Based on your wiki, I know you did a lot of testing and have the capacity to demonstrate part success; however, remember to present your research items in a way that is mindful to someone who is outside of your experimental realm. Ask yourself the following questions: 1) What specifically was successful about my part design? 2) If quantifying data and showing that data in another means (e.g. microscopy images) do these images match? 3) What caveats and troubleshooting would be necessary to bring this part further? Another note, and it is minor, but in your human practices and promotion of the BFH European meetup, you bring attention to connections and participation by two high-profile iGEM members (Nemanja - VP, Tracy - Former Director of Judging). While it is okay to demonstrate their attendance (using videos of them, describing what they do), it feels borderline like favoritism in that they were showing up to your event, in particular with you highlighting their attendance, not necessarily what they presented on and how it impacted you and the other teams in attendance. Be mindful of this going forward.</p>
+ </div>
+ </div>
+
+ <H4 text="Judge 4"></H4>
+ <div className="row feedbackbfh">
+ <div className="col b-lg">
+ <p>Your project is very good; I like the approach, as we are used to seeing more invasive approaches in medicine. Your project was also very well defended; you answered the questions confidently, which caught my attention. You never hesitated. It was a lot of work, and you managed to shape it well. I hope you can continue with the project and turn it into a startup</p>
+ </div>
+ <div className="col b-lo">
+ <p>It would be useful to delve into the potential challenges related to the biocompatibility and degradability of chitosan nanoparticles in the human body, as ensuring long-term safety and efficacy is essential for therapies of this kind. It would also be interesting to explore methods and experiments to further improve the stability of the nanoparticles, evaluate different pH conditions, and determine which peripheral cells or tissues could be harmed or could benefit. Let's remember that the human body is not an isolated system; many of these interactions may lead to allergies, unwanted responses, or affect the organism's suitability. Cultivating peripheral tissues with the same system would also be a very intriguing approach.</p>
+ </div>
+ </div>
+
+ <H4 text="Judge 5"></H4>
+ <div className="row feedbackbfh">
+ <div className="col b-lg">
+ <p>You demonstrated a strong commitment to biosafety by outlining detailed safety protocols and addressing both environmental and human health risks. Your proactive approach to identifying potential hazards and implementing safety measures highlights your responsibility in managing synthetic biology risks. Great work!</p>
+ </div>
+ <div className="col b-lo">
+ <p>Your Materials and Methods section provides a solid foundation of your technical work, but could benefit from more detailed explanations of some experimental design choices. Additionally, including a section that discusses challenges encountered and how you have addressed it would offer valuable insights for future teams attempting to replicate or build on yourwork. This would also help illustrate the adaptability and problem-solving aspects of your project</p>
+ </div>
+ </div>
+
+
+ <H4 text="Judge 6"></H4>
+ <div className="row feedbackbfh">
+ <div className="col b-lg">
+ <p>The integration of Prime Editing and the AirBuddy delivery system showcases a cutting-edge approach to gene therapy. This not only demonstrates technical innovation but also highlights your commitment to improving treatment efficacy and precision.</p>
+
+ </div>
+ <div className="col b-lo">
+ <p>While the therapy aims for long-term correction, discussing how you plan to evaluate durability and stability of the genetic correction over time could provide a clearer understanding of the treatment’s potential benefits.</p>
+ </div>
+ </div>
+ </Section>
</>
);
diff --git a/src/contents/methods.tsx b/src/contents/methods.tsx
index 81604f047415bd3954e4dce5a0833faf7d0125f3..b2b7e75abc00ba086923adeeb1fbaf7f83bad4d9 100644
--- a/src/contents/methods.tsx
+++ b/src/contents/methods.tsx
@@ -23,7 +23,11 @@ export function Methods() {
<p>Patch clamp recording involves the use of a glass micropipette which is manufactured from a glass capillary through the use of a Micropipette Puller. The micropipette is then filled with an electrolyte solution, which is subsequently brought into contact with the cell membrane. By applying gentle suction, a high-resistance seal called giga seal is formed between the pipette tip and the membrane patch. This enables the measurement of ionic currents with minimal noise interference [3]. <strong>Whole-Cell Configuration</strong> records currents from the entire cell by rupturing the membrane patch, accessing the intracellular environment, and is useful for analysing overall ion channel activity and cellular responses. <strong>Single-Channel Recording</strong> measures currents through individual ion channels without rupturing the membrane, enabling high-resolution study of channel conductance, gating, and selectivity [2].</p>
<div className="figure-wrapper">
<figure>
- <iframe title="Bielefeld-CeBiTec: Patch Clamp Measurement (2024)" width="560" height="315" src="https://video.igem.org/videos/embed/0d948e57-5997-430a-a2df-815b71a2fc67?autoplay=1" frameBorder="0" allowFullScreen={true} sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
+ <div className="row align-items-center">
+ <div className="col">
+ <iframe title="Bielefeld-CeBiTec: Patch Clamp Measurement (2024)" width="560" height="315" src="https://video.igem.org/videos/embed/0d948e57-5997-430a-a2df-815b71a2fc67?autoplay=1" frameBorder="0" allowFullScreen={true} sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
+ </div>
+ </div>
<figcaption> <b>Figure 1. </b> Microscopic recording of micropipette sealing of a HEK293 cell. </figcaption>
</figure>
</div>
diff --git a/src/contents/notebook.tsx b/src/contents/notebook.tsx
index dc5705de6d80f59d440593f7d1b58d1311d5cfa9..94f51b462d5b5cc4573e286c3dee35efea52123a 100644
--- a/src/contents/notebook.tsx
+++ b/src/contents/notebook.tsx
@@ -22,7 +22,7 @@ export function Notebook() {
</div>
<div className="col">
- <DownloadImageButton url="" fileName="">
+ <DownloadImageButton url="https://static.igem.wiki/teams/5247/pdfs/laboratory-notebook-2-engineering-our-prime-editing-tool-primeguide.pdf" fileName="laboratory-notebook-2-engineering-our-prime-editing-tool-primeguide.pdf">
<img src="https://static.igem.wiki/teams/5247/lab-journals/titelseite-lab-book-2-engineering-pe.webp" style={{height: "75%", width: "auto"}}/>
</DownloadImageButton>
</div>
diff --git a/src/contents/project-documentation.tsx b/src/contents/project-documentation.tsx
index 44afcdb85b1cc49bf75faade99b76aebc555c063..7183ea21f190aa1d61f3c7068058d6390ee786cc 100644
--- a/src/contents/project-documentation.tsx
+++ b/src/contents/project-documentation.tsx
@@ -1,4 +1,3 @@
-import { Calendar } from "../components/Calendar/Calendar";
import { H2 } from "../components/Headings";
import { PDF } from "../components/Pdfs";
import { useTabNavigation } from "../utils/TabNavigation";
@@ -10,7 +9,6 @@ export function ProDesc() {
<div className="col">
<H2 text="Our Meeting Protocols"/>
<PDF link="https://static.igem.wiki/teams/5247/pdfs/meetings.pdf" name="meetings.pdf"/>
- <Calendar/>
</div>
);
}
diff --git a/src/contents/results.tsx b/src/contents/results.tsx
index 44098c7a40570d4b44ed6da21c0120ee11bdc0e5..d920714efa66944e413fe980c585ab1f389b0728 100644
--- a/src/contents/results.tsx
+++ b/src/contents/results.tsx
@@ -9,6 +9,8 @@ import { DownloadLink } from "../components/Buttons";
import { OneFigure, ThreeVertical, TwoHorizontal, TwoVertical } from "../components/Figures";
import { ResTable } from "../components/Table";
import { headercols, resultdata } from "../data/results-table";
+import { SupScrollLink } from "../components/ScrollLink";
+import ResultSources from "../sources/res-sources";
export function Results() {
@@ -380,7 +382,7 @@ export function Results() {
/>
</div>
</div>
- <p>Overall, while the Cryo-EM data confirm the presence and general morphology of LNPs that also fall within the diameter range specified by Wang et al. for SORT LNPs at smaller than 200 nm [1]. The variability in size and the presence of aggregates highlight potential areas for optimization, such as refining sample concentration and preparation methods to achieve more consistent particle formation.</p>
+ <p>Overall, while the Cryo-EM data confirm the presence and general morphology of LNPs that also fall within the diameter range specified by Wang et al. for SORT LNPs at smaller than 200 nm <SupScrollLink label="1"></SupScrollLink>. The variability in size and the presence of aggregates highlight potential areas for optimization, such as refining sample concentration and preparation methods to achieve more consistent particle formation.</p>
<H5 text="DLS"/>
<p>We used Dynamic Light Scattering (DLS) to assess the size distribution of our SORT LNPs by measuring the fluctuations in scattered light due to particle motion. The hydrodynamic diameter was calculated using the Stokes-Einstein equation, considering the diffusion coefficient, temperature, and viscosity of the medium.</p>
<div className="row align-items-center">
@@ -542,7 +544,7 @@ export function Results() {
/>
</div>
<div className='col'>
- <p>In our first set of experiments, we measured current density in <a onClick={() => goToPageAndScroll ('Cell Culture', '/materials-methods')}>HEK293T CFTR wild type (WT) and HEK293T F508del</a> cell lines, comparing them with regular HEK293. The results demonstrated significant differences in chloride ion conductance, with the CFTR-expressing cell lines showing enhanced conductivity compared to HEK293 (Figure 37). However, a drawback was that we did not observe any significant differences between the HEK293T CFTR WT and F508del cell line. This was unexpected, as the F508del mutation typically leads to a knockdown of the CFTR protein[2], impairing chloride ion transport through the CFTR channel.</p>
+ <p>In our first set of experiments, we measured current density in <a onClick={() => goToPageAndScroll ('Cell Culture', '/materials-methods')}>HEK293T CFTR wild type (WT) and HEK293T F508del</a> cell lines, comparing them with regular HEK293. The results demonstrated significant differences in chloride ion conductance, with the CFTR-expressing cell lines showing enhanced conductivity compared to HEK293 (Figure 37). However, a drawback was that we did not observe any significant differences between the HEK293T CFTR WT and F508del cell line. This was unexpected, as the F508del mutation typically leads to a knockdown of the CFTR protein<SupScrollLink label="2"></SupScrollLink>, impairing chloride ion transport through the CFTR channel.</p>
</div>
</div>
<H4 text="Further Validation and Challenges"/>
@@ -568,6 +570,7 @@ export function Results() {
<p><DownloadLink url="https://static.igem.wiki/teams/5247/pdfs/raw-data-patch-clamp.pdf" fileName="raw-data-patch-clamp.pdf" /> Supplementary Material for Patch Clamp</p>
<DownloadLink url="https://static.igem.wiki/teams/5247/pdfs/raw-data-delivery.pdf" fileName="raw-data-delivery.pdf" /> Supplementary Material for Delivery
</Section>
+ <ResultSources/>
</>
);
}
diff --git a/src/data/hptimelinedata.tsx b/src/data/hptimelinedata.tsx
index ccfa649a1a7c11e4e48cbe69b4e66b2ce4e1b0c0..ddd773d3f2a23f6aae7ec2697db54ecc4317be3a 100644
--- a/src/data/hptimelinedata.tsx
+++ b/src/data/hptimelinedata.tsx
@@ -164,7 +164,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
The multidisciplinary structure of this team evolved naturally as they identified the project’s needs and recruited members who could fill specific roles. Over time, this multidisciplinary structure has continued to develop as the team’s project evolved. Roles became more defined as team members took on specific responsibilities, whether it was refining prime editing systems or crafting
communication strategies for iGEM. The range of experience across the team, from younger students like Malte Lenger in the early stages of their academic careers to more advanced students in later semesters, like Lisa Wiesner, allows for a blend of fresh perspectives and seasoned expertise. This balance helps ensure both the immediate success of the project and the continuity of its progress in the future.
In summary, this interdisciplinary iGEM team demonstrates how a diverse group of individuals with specialized skills can come together to tackle a complex biological project. By combining their expertise the team is able to execute their project holistically, ensuring that each aspect, from experimental design to public outreach, is handled with precision and creativity.</p>],
- months: "February"
+ months: "feb"
},
{
vorname: "Pitching ideas",
@@ -186,7 +186,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<p>We also considered a project aimed at preventing <b>cyanobacteria blooms</b> using peptides or proteins derived from algae. Cyanobacteria can produce harmful toxins that degrade water quality and threaten ecosystems. The proposed approach focused on utilizing natural algae to develop mechanisms that inhibit the growth of harmful cyanobacteria without disrupting the ecosystem. This project emphasized conservation and biodiversity while addressing a significant environmental issue linked to the climate crisis.</p>,
<p>Throughout our discussions, we recognized that while each project had merit, the <b> Cystic Fibrosis</b> initiative offered the most promise for a targeted approach to a well-defined problem. CF, affecting a substantial number of individuals, provided a clear opportunity for meaningful impact through gene therapy. The insights gained from our examination of other projects informed our approach to CF, allowing us to integrate knowledge from diverse fields and methodologies, ultimately shaping a comprehensive and innovative project direction.</p>
],
- months: "March"
+ months: "mar"
},
{
vorname: "Ideation in Hamburg",
@@ -204,18 +204,9 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
summary: [<p>From April 5th to 7th, we embarked on an enriching excursion dedicated to project work and team building. Our primary goal was to engage in meaningful brainstorming sessions focused on our iGEM project and to explore human practices thoroughly.
We kicked off our weekend with a series of discussions that emphasized the importance of considering the impact of our work on the world. </p>,
<p>Throughout our time in Hamburg, we dedicated several hours to reading relevant literature and research papers, both individually and in groups. This collaborative effort allowed us to deepen our understanding of existing projects and innovations in our field. We critically analyzed previous iGEM projects and explored who had worked on similar ideas, which helped us identify gaps in the research and potential avenues for our own project.
- Our discussions naturally flowed into brainstorming sessions where we reflected on the impacts we wanted to achieve. We explored essential questions: What effects do we aim to have on society? What activities can we plan to gather evidence about how our work will resonate with the community? How can we effectively engage with stakeholders and share our findings?</p>,
- <p>In addition to structured brainstorming, we exchanged ideas informally during breaks and meals, fostering a creative atmosphere. By the end of the weekend, we had not only strengthened our team bonds but also clarified our vision for the project ahead. The insights gained from our discussions and readings laid a solid foundation for our future work, allowing us to approach our project with renewed focus and purpose. </p>],
- insights: [<div className="row">
- <div className="col"><img src="https://static.igem.wiki/teams/5247/photos/hp/teambuilding-hamburg.webp"></img>
- </div>
- <div className="col"><p>Our first event in Hamburg was a meeting with the Hamburg iGEM team. Overlooking the Alster lake, we exchanged ideas and got to know each other. The collaboration with <OurLink path='contribution'tabId='contribution' scrollToId='bfh-european-meetup' text="BFH"/> {/*Kaya*/} was strengthened by this meeting with iGEM Hamburg. Suddenly we were surprised by the typical Hamburg weather. However, we did not let this spoil our good mood. In small groups we explored Hamburg and braved the rain. We also visited the University of Hamburg and socialised a lot.</p>
- <br/>
- <p>On Saturday we started the most important part of our trip. Our project! The whole team gathered on the roof terrace in the bright sunshine and extensive research began. We had already chosen a general topic in Bielefeld, but now we had to narrow it down. To do this, we diligently read various publications, made notes and exchanged ideas. Later, the team met again on the roof terrace to continue researching and discussing. Thanks to our in-depth research phase, we were able to gather many insightful ideas. The workshop was very productive and moved us forward significantly, allowing us to have a clear vision of our project by the end of the day. We now have a strong foundation to build on as we continue to develop the concept. So it was a great success! This was followed by the evening cooking session where the whole team was treated to a very tasty 3-course meal. We are already looking forward to Paris because we want to cook together in the evening and meet other iGEMers as well as Team Hamburg! </p>
- <br/>
- <p>Sunday morning started again with breakfast in the hostel. After checking out we walked in the bright sunshine to the Landungsbrücken, a kind of tourist landmark of Hamburg. We ate donuts and had a fantastic view of the Elbe, Hamburg's most famous river. We wanted to use the last day to see a bit more of Hamburg as a team. The return journey was used productively to read more papers and do more research for our project. </p></div>
- </div>],
- months: "March"
+ Our discussions naturally flowed into brainstorming sessions where we reflected on the impacts we wanted to achieve. We explored essential questions: What effects do we aim to have on society? What activities can we plan to gather evidence about how our work will resonate with the community? How can we effectively engage with stakeholders and share our findings?
+ In addition to structured brainstorming, we exchanged ideas informally during breaks and meals, fostering a creative atmosphere. By the end of the weekend, we had not only strengthened our team bonds but also clarified our vision for the project ahead. The insights gained from our discussions and readings laid a solid foundation for our future work, allowing us to approach our project with renewed focus and purpose.</p>],
+ months: "mar"
},
{
vorname: "Max",
@@ -299,7 +290,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Are most of the other patients you know in good health like you?" a="No. Another boy my age got a fungal infection and does not have long time left to live. " />
</>,
summary: "We reached out to Max, a friend of a teammate, to gain insights into the needs and experiences of CF patients. Our discussions revealed the challenges faced by CF patients, even those in relatively good health, and emphasized the ongoing need for new treatment options. Max's candid sharing of his experiences highlighted the limitations of current modulators, the importance of lung function, and the impact of treatments on quality of life. This meeting transformed our project perspective, urging us to prioritize safety and real-world benefits in our design. Ultimately, Max's influence led us to focus on lung-targeted gene therapy instead of a diagnostic approach, reinforcing our commitment to Integrated Human Practices.",
- months: "April",
+ months: "apr",
/*interview:<iframe title="Bielefeld-CeBiTec: Interview with Max Beckmann (2024) [English]" width="560" height="315" src="https://video.igem.org/videos/embed/16501867-a687-4205-949a-51ead876e109" frameborder="0" allowfullscreen="" sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>,*/
},
{
@@ -316,7 +307,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteNachname: "Sanfilipo, Teammember",
quoteVorname: "Liliana",
summary: "Our team members had a productive visit to the Hannover Messe, focusing on synthetic biology and research advancements. They explored innovative technologies and networked with potential sponsors, gaining valuable insights to help enhance our project and drive future developments. The event was a great opportunity to connect with industry leaders and learn about cutting-edge solutions in the field.",
- months: "April",
+ months: "apr",
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/hp/hannover-1.webp",
},
{
@@ -340,7 +331,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
On the other hand, LNPs offer a scalable and re-dosable alternative. LNPs have the advantage of a larger packaging capacity, allowing them to carry more complex genetic instructions or larger gene-editing tools, such as prime editors. They are also easier and cheaper to produce on a large scale, making them an attractive option for widespread clinical applications. A significant benefit of LNPs is their lower immunogenicity, which reduces the risk of adverse immune reactions upon repeated dosing. However, LNPs currently face challenges in specific targeting compared to AAVs. AAVs have a higher precision in targeting specific tissues, while LNPs still need optimization for targeted delivery to areas like the lungs.</p>],
implementation: [<p>Prof. Müller’s insights directly inform the implementation of our iGEM project, where we aim to design novel prime editors that are small enough to be delivered efficiently, while also exploring LNPs <OurLink path='engineering'tabId='delivery' scrollToId='del1head' text="exploring LNPs"/> as a scalable and re-dosable alternative to AAVs. By tailoring our approach to address the specific challenges of CF, such as mucus penetration and lung cell targeting, we can enhance the precision and efficacy of gene therapy. These innovations have the potential to set new standards in the field and contribute to broader research on genetic disease treatment.</p>],
summary: [<p>In our interview with Prof. Dr. Kristian Müller, we explored the revolutionary potential of prime editing as a next-generation gene editing technology. Prof. Müller highlighted the advantages of prime editing over traditional CRISPR-Cas systems, particularly its ability to make precise genetic modifications without double-strand breaks, thus reducing off-target effects. He emphasized the importance of optimizing delivery systems, such as <OurLink path='engineering'tabId='delivery' scrollToId='del1head' text="AAV and LNPs"/>, and discussed the ethical considerations and biosafety measures crucial for advancing gene therapy. The interview underscored the significance of Cystic Fibrosis as a model disease, given its prevalence and the potential for impactful treatments through targeted genetic corrections.</p>],
- months: "April",
+ months: "apr",
interview:<><iframe title="Bielefeld-CeBiTec: Interview Müller AAV vs LNP (2024) [English]" width="560" height="315" src="https://video.igem.org/videos/embed/0613b6b8-7755-4373-9d86-9910fe30781f" frameBorder="0" allowFullScreen={true} sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe><p>This interview was recorded on video at a later date.</p></>,
},
{
@@ -380,7 +371,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
],
- months: "April"
+ months: "apr"
},
{
vorname: "Visiting ",
@@ -440,7 +431,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
affiliation: "OWL University Hospital",
pictureurl: pics['olariu'],
tag: "Medical Professional",
- heading: "Discussion with a pediatrician and his former patient about treatment challenges and perspectives",
+ heading: "Discussion with a pediatrician about treatment challenges and perspectives",
interviewtabid: "olariu",
language: "de",
@@ -522,7 +513,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
affiliation: "Independent",
pictureurl: pics['westhoff'],
tag: "Medical Professional",
- heading: "Interview with a specialized physiotherapist regarding breathing therapy for Cystic Fibrosis patients",
+ heading: "Interview with a specialized physiotherapist regarding breathing therapy",
interviewtabid: "westhoffinv",
language: "de",
@@ -563,7 +554,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
affiliation: "Stemcell",
pictureurl: pics['stemcell'],
tag: "Industry",
- heading: "Longstanding Support from Stemcell Expert in Cell Culture Media and Primary Cell Cultivation",
+ heading: "Longstanding Support in Cell Culture Media and Primary Cell Cultivation",
interviewtabid: "michaela",
language: "de",
@@ -738,7 +729,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</>,
references: <MattijsInterviewSources />,
summary: "Our discussion with Mattijs Bulcaen from KU Leuven provided critical insights into the complexities of using prime editing for CF therapy. As we began designing our prime editor, Mattijs highlighted challenges specific to targeting the CFTR F508del deletion, including the influence of mismatch repair systems and chromatin organization on editing efficiency. He introduced us to advanced techniques, such as PE3b systems and dsgRNAs, and recommended using the 3’ stem loop motif from his research to enhance our pegRNA design. Additionally, he advised utilizing HEK cell lines for screening due to their ease of handling and reduced mismatch repair activity. These insights directly influenced our design choices and helped refine our approach to developing an effective prime editing strategy.",
- months: "june"
+ months: "jun"
},
{
vorname: "Integrate Insights",
@@ -769,7 +760,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<b>Scientific Advancements:</b> Improved the efficiency of Prime Editing by incorporating a novel RNA structural element, with further efforts to optimize the Prime Editing protein complex for broader applicability beyond Cystic Fibrosis.
</li>
</ul>],
- months: "june"
+ months: "jun"
},
{
vorname: "'Der Teuto ruft'",
@@ -786,7 +777,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteVorname: "Asal",
quote: "I had a great time educating the kids about gene therapy and CF in a playful way, and there were some very interesting conversations with the parents.",
summary: [<p> <OurLink tabId='teutoruft' scrollToId="teuroruft-heading" path='human-practices' text="Der Teuto ruft!"/> is a community event in Bielefeld where iGEM Bielefeld participated to raise awareness about Cystic Fibrosis (CF) and gene therapy. They engaged children through interactive experiments, such as creating lung models and simulating mucus to help them understand the challenges faced by CF patients. Adults were informed about their gene therapy project and had meaningful discussions about the implications of CF treatment. Collaborating with other institutions like the life science student initiative btS, the team expanded their outreach. Despite changeable weather, the event was a success in educating the public and improving science communication.</p>],
- months: "June"
+ months: "jun"
},
{
vorname: "Julia",
@@ -833,7 +824,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="How do you handle communicating about her illness?" a="We try not to make a big deal of it. When I looked for information, I found what we needed. There’s nothing we’ve really felt was missing." />
</>,
summary: "Julia's insights shifted our focus to the support systems surrounding CF patients. She highlighted the societal implications of CF, including rising healthcare costs due to the long-term nature of treatment and the financial burdens faced by families. Additionally, Julia emphasized the emotional strain that accompanies the illness, alongside the complexities of parenting a child with CF. Importantly, she affirmed that most children adapt well to inhalative therapies, reinforcing our planned delivery method for gene therapy. This interview enriched our understanding of the challenges faced by families and enabled us to better compare the experiences of CF patients in Germany to those in other countries.",
- months: "june"
+ months: "jun"
},
{
title: "Prof. Dr.",
@@ -863,7 +854,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
],
implementation: "x",
summary: " David Liu, the principal investigator behind prime editing systems, has significantly contributed to the development of advanced gene editing techniques, including applications for the CFTR mutation F508del. His research provided valuable insights for our project, leading us to adopt a system based on the PE6c and PE4 prime editors. Although we couldn't directly engage with Liu or his team, the impact of his work is evident in our gene editing approach for PreCyse. Notably, Liu's recent talk at the 'State of CRISPR and Gene Editing 2024' conference highlighted advancements such as improved reverse transcriptases and their applications in prime editing. The publication of his findings on CFTR F508del correction in July 2024 further validated our design choices for pegRNA and offered new strategies for optimizing our approach.",
- months: "June",
+ months: "jun",
references: <LiuInterviewSources/>,
},
{
@@ -924,7 +915,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
a="It’s mainly interdisciplinary. A lot of funding comes from industry, like BioNTech, or foundations like Mukoviszidose e.V., which funds research on Cystic Fibrosis. But in terms of practical research, it’s usually biologists or biotechnologists. Without industry support, research can struggle due to a lack of funding, so having backing is essential." />
</>,
summary: "Our discussion addressed the complexities of Cystic Fibrosis (CF) treatments, focusing on gene therapy and health insurance processes. We learned about the regulatory challenges gene therapies face, particularly regarding the European Medicines Agency (EMA) and the AMNOG process for reimbursement assessments. Public insurers impose stricter guidelines than private insurers, emphasizing the importance of early intervention in CF and the need for adaptable policies for atypical cases. We recognized the high costs associated with gene therapies and incorporated cost-benefit analysis into our project planning. Following the interview, we refined our approach to include straightforward delivery methods and attended a GxP course for regulatory compliance. Engaging with start-ups further informed our practical implementation strategies, ensuring our project aligns with both scientific and regulatory needs.",
- months: "june",
+ months: "jun",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/zoom-nicole.webp",
},
{
@@ -946,7 +937,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<p>Understanding rigorous quality control processes was another key takeaway, enabling us to implement checks that will boost the reliability and safety of our therapeutics. These comprehensive insights have not only supported our current goals but also prepared us for future challenges, equipping us with the tools to navigate the complexities of research and therapeutic development.</p>],
implementation: [<p>Discussions with industry experts have provided invaluable insights into the production of LNPs{/* [LINK LNPcycle] */}, a crucial aspect of our project. We have identified innovative manufacturing techniques and quality control procedures that we can integrate into our processes. This knowledge not only supports our immediate objectives but also positions us to overcome future challenges in developing effective therapies.</p>],
summary: [<p>During discussions with industry experts at Achema 2024, we gained valuable insights that will have a significant impact on our project and provide us with innovative manufacturing techniques and quality control procedures that we are now integrating into our workflows. These insights will help us to optimise our production processes to achieve more efficient and reliable results in therapeutic development. The new knowledge supports our current goals and prepares us for future challenges in the development of effective therapies</p>],
- months: "june",
+ months: "jun",
pictureurl_aim:"https://static.igem.wiki/teams/5247/photos/hp/achema1.webp",
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/hp/achema2.webp",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/achema3.webp",
@@ -987,7 +978,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</ol>,],
summary: "In the visit with Katrin Westhoff, we participated in physiotherapy sessions for children, including those with Cystic Fibrosis (CF). We observed that breathing therapy is beneficial for various illnesses and learned techniques that can be practiced at home. Sessions last 30 to 60 minutes, combining manual therapy with playful elements. While older children engaged well, infants often found the exercises uncomfortable. Importantly, both Katrin and parents noted that children could inhale without issues from an early age, reinforcing our focus on inhalation delivery methods for therapies.",
pictureurl_interview:"https://static.igem.wiki/teams/5247/photos/hp/besuch-westhoff/untitled-design.png",
- months: "june"
+ months: "jun"
},
{
title: "Dr.",
@@ -1013,7 +1004,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Storage conditions were strictly managed at 4 °C, and pipetting/mixing techniques were refined to ensure quality consistency. Quality control was expanded to include fluorescence testing, zeta potential measurements, and light scattering, alongside cytotoxicity tests.
These improvements not only address transfection challenges but also strengthen our foundation for future LNP applications. </p>],
summary: "The aim of the contact was to address challenges in LNP transfection and improve formulation protocols for enhanced gene delivery. Dr. Radukic highlighted the importance of lipid-to-nucleic acid ratios, recommending adjustments like 10:1 for better transfection efficiency. He also emphasized optimizing pH and buffer composition, as well as strict storage and mixing practices. Additionally, quality control measures such as fluorescence testing and zeta potential analysis were suggested to ensure LNP stability. These insights were implemented into the project, improving transfection efficiency and paving the way for future LNP applications.",
- months: "June"
+ months: "jun"
},
{
title: "Prof. Dr.",
@@ -1075,7 +1066,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</>,
summary: "In summary, through the interview with Prof. Dr. Wischmeyer and the collaboration with his employee Dr. Oliver Dräger, we gained valuable insights and optimized our approach to effectively investigate and measure the functionality of the CFTR ion channel, thereby determining the efficiency of our prime editing strategy.",
- months: "june"
+ months: "jun"
},
{
vorname: "Joshua",
@@ -1121,7 +1112,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/joshua-zoom.webp",
references: <JoshuaInterviewSources />,
summary: "Joshua, a CF parent living in Thailand, shared his experiences about the severe challenges of accessing CF care in regions like Southeast Asia. His story highlighted the racial bias and lack of medical knowledge about CF in these areas. This interview prompted the team to reflect on their focus on the F508del mutation, questioning if their research was biased towards more commonly studied mutations. After revisiting their research process, they found that the F508del mutation remains globally relevant, yet the experience reinforced the importance of addressing gaps in healthcare and research for underrepresented regions.",
- months: "July"
+ months: "jul"
},
{
vorname: "Close the Loop",
@@ -1161,7 +1152,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
],
- months: "july"
+ months: "jul"
},
{
title: "Prof. Dr.",
@@ -1199,7 +1190,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<p>We developed our mutation candidates on this basis. {/*[link zum Cycle oder New Part ?]*/}</p>
],
summary: "In our discussion with Prof. Dr. Hammer, we explored several theoretical approaches in enzyme engineering, including PAM engineering, chimeric proteins, Phage-Assisted Continuous Evolution (PACE), and rational design involving zinc-finger mutations. We evaluated the potential of using structural simulations with AlphaFold 3 and the construction of chimeric proteins. The conversation highlighted the importance of analyzing homologous mechanisms through sequence alignments to identify structural similarities in catalytic centers. We also discussed targeted mutations, such as substitutions to alanine, and the development of a nickase assay. Overall, we concluded that transferring mutations to homologous proteins is a promising rational approach for optimizing enzyme function.",
- months: "July"
+ months: "jul"
},
{
vorname: "Steffen Bira and",
@@ -1239,7 +1230,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What is Corden Pharma's position on projects involving gene therapy?" a="Corden Pharma operates as a service provider, focusing on the manufacturing of active pharmaceutical ingredients (APIs) and excipients rather than developing therapeutic products. Consideration should be given to the intellectual property status of the lipids used in LNP formulations, particularly for commercial applications."/>
</>,
summary: "The primary goal of the communication with Steffen Bira and Serra Gürcan from Corden Pharma was to explore the use of Lipid Nanoparticles (LNPs) in gene therapy and inhalation treatments. Corden Pharma recommended consulting specialists for assessing spray drying feasibility, while highlighting the importance of testing LNP stability under various conditions. Their LNP starter kits are optimized for stability and encapsulation efficiency, with potential for lipid modifications to enhance cellular uptake. They also confirmed that antibodies can be incorporated into LNPs and emphasized considering intellectual property when selecting lipids. Based on Corden Pharma’s insights, we switched to their kit #2 for our project, hoping to improve the stability and efficiency of our LNP formulations. Their guidance also opened opportunities for targeted therapies and collaborations. This feedback will continue to enhance our testing and therapeutic approaches.",
- months: "july",
+ months: "jul",
pictureurl_interview:"https://static.igem.wiki/teams/5247/photos/hp/hp-corden-zoom.png"
},
{
@@ -1255,7 +1246,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteVorname: "Kaya",
quote: "It was amazing to see how exciting the conversations were with future STEM scientists and to hear the fresh perspectives from young minds. The entire experience was both inspiring and energizing.",
summary: [<p>MINT Sommer 2024 is a program for high school graduates interested in STEM fields, and iGEM Bielefeld participated to raise awareness about CF and promote their gene therapy research. The team engaged future scientists, explaining the iGEM competition and their synthetic biology approach to address CF. Using insights from previous workshops, they designed interactive activities to make the complexities of CF accessible to attendees. Over two weeks, they formed meaningful connections with professors, students, and STEM professionals, enriching their research discussions. Overall, the event helped improve their science communication skills and fostered valuable professional growth.</p>],
- months: "July"
+ months: "jul"
},
{
title: "Dr.",
@@ -1284,7 +1275,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
],
implementation: [<p>On the basis of Svenja’s and other opinions on the topic, we decided not to try implementing a PACE system. </p>],
summary: "We reached out to Svenja Vinke, a former iGEMer and Postdoc, to gain insights on using phage-assisted continuous evolution (PACE) for optimizing our prime editing. Svenja explained that a PACE approach is not feasible for our nickase candidates due to several reasons: it requires too much time, endonucleases are likely too large for optimization, unspecific cutting can kill bacterial cells, and prime editing is less effective in E. coli than in human cells. Based on Svenja's feedback and other expert opinions, we decided against implementing a PACE system for our project.",
- months: "July"
+ months: "jul"
},
{
title: "Dr.",
@@ -1303,7 +1294,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "The discussion was very informative in terms of how we should approach this topic and focused primarily on the important factors that need to be considered when planning the handling of patient cells. These include which legal principles need to be observed, data protection, ethical considerations and, above all, detailed and specific information for the donor. It also made us look at the situation from many different angles and consider the risks of worst-case scenarios. Overall, this interview was very useful to us, and we were able to use the information we gained to develop a kind of guideline that allowed us to approach this sensitive topic, which was new to us, with a certain degree of confidence. ",
implementation: "Based on the knowledge we have gained, we have drawn up guidelines for our handling of the cells. We used this guide when handling the patient cells, to ensure they were handled in an ethically correct manner.",
summary: "This interview focused on the ethical and legal considerations of handling patient cells, we sought to determine whether our project required an ethics vote and to gather guidelines on data protection and patient consent. The expert emphasized the importance of providing patients with a detailed consent letter and privacy policy, clearly explaining how their cells and data will be used, who will have access, and the time span involved. This conversation helped us understand key legal and ethical principles, especially regarding transparency with donors. We used these insights to develop guidelines for handling patient cells, ensuring we approached this sensitive process with confidence and ethical care.",
- months: "July",
+ months: "jul",
pictureurl_interview:"https://static.igem.wiki/teams/5247/integrated-human-practices/interview-berens.webp",
},
{
@@ -1326,7 +1317,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Lastly Mattijs explained how he plans to deliver the prime editing complex to the patient, and we evaluated the advantages and disadvantages of delivery strategies, including our very own LNP approach.</p>],
implementation: [<p>When planning how to test and confirm editing by our own constructs, we were largely inspired by the information given to us by Mattijs. For example, we tested prime editing in the HEK293 cell lines we spoke about with Mattijs and used halide sensitive eYFP to check for CFTR function. Also, we tried differentiating wild-type and F508del cells using patch clamp. Unfortunately, a lot of the methods mentioned were not usable for us because of time constraints, but are still valuable for future projects and research built upon PreCyse. </p>],
summary: "We visited Mattijs Bulcaen in Leuven to enhance our understanding of CFTR F508del models and editing confirmation. During the visit, we examined HEK293T cell lines that stably overexpress wild-type CFTR and the F508del variant. Mattijs demonstrated how to use a 3HA tag for visualizing protein processing and discussed methods for assessing CFTR functional recovery. We also compared Sanger and Nanopore sequencing techniques and evaluated delivery strategies for our prime editing complex. The insights from this visit guided our project, leading us to test prime editing in HEK293T cells using halide-sensitive eYFP. While some methods were not feasible due to time constraints, they laid the groundwork for future research in the PreCyse project.",
- months: "july"
+ months: "jul"
},
{
vorname: "Collaborations",
@@ -1342,7 +1333,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteVorname: "Kaya",
quoteNachname: "Lange",
quote: "We were genuinely excited when Linköping University approached us for collaboration. From the very beginning, their ideas resonated with us, and our shared enthusiasm laid a strong foundation for a productive partnership. We're happy to work together, also with the other teams, and explore new possibilities.",
- aimofcontact: [<p>The initial contact for our collaboration came from the iGEM team 2024 of Linköping, Sweden, who approached us with a proposal to create a “Delivery-Based Handbookâ€[link Handbook]. Their goal was to reduce the steep learning curve associated with these technologies by sharing collective knowledge from multiple teams, including ours. We were excited to contribute and help future teams navigate these challenges more easily. The handbook would serve as a valuable tool. </p>],
+ aimofcontact: [<p>The initial contact for our collaboration came from the iGEM team 2024 of Linköping, Sweden, who approached us with a proposal to create a <OurLink path="contribution" scrollToId="Our Collaborations2H" text="“Delivery-Based Handbookâ€"/>. Their goal was to reduce the steep learning curve associated with these technologies by sharing collective knowledge from multiple teams, including ours. We were excited to contribute and help future teams navigate these challenges more easily. The handbook would serve as a valuable tool. </p>],
insights: [<p>Throughout the collaboration, we gained significant insights, both scientific and collaborative. Initially, our meetings with the Linköping team and other participating teams - Patras, Radboud-University and TERMOSZ-Selye-HUN - were invaluable. These sessions allowed us to exchange ideas and learn how each team planned to use lipid-based delivery systems in their own projects. This mutual sharing of knowledge opened our eyes to new methodologies and potential applications of LNPs and liposomes. We also gained a deeper appreciation for the interdisciplinary nature of these systems. From the challenges of formulating stable particles to optimizing their efficiency in targeting cells, we realized the complexity of the field and how collaboration could help overcome many of these obstacles. By discussing our respective approaches, we were able to pool our expertise, which not only improved our understanding but also ensured that the handbook would be comprehensive and valuable for various iGEM teams, regardless of their specific project focus.
In summary: </p>,
<ul>
@@ -1353,7 +1344,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<li>Focused on documenting work to benefit future iGEM teams.</li>
</ul>
],
- implementation: [<p>The collaboration expanded our understanding of what's possible, inspiring us to consider new ideas for how we might integrate advanced techniques into our nanoparticle systems in future projects. The collaborative process also encouraged us to document our work more thoroughly, ensuring that future iGEM teams could benefit from both our successes and the challenges we encountered along the way. Beyond the technical improvements, the experience taught us the value of teamwork across borders and disciplines. Each team brought a unique perspective, and by working together, we were able to develop a resource that was far greater than the sum of its parts</p>],
+ implementation: [<p>The collaboration expanded our understanding of what's possible, inspiring us to consider new ideas for how we might integrate advanced techniques into our nanoparticle systems in future projects. The collaborative process also encouraged us to document our work more thoroughly, ensuring that future iGEM teams could benefit from both our successes and the challenges we encountered along the way. Beyond the technical improvements, the experience taught us the value of teamwork across borders and disciplines. Each team brought a unique perspective, and by working together, we were able to develop a resource that was far greater than the sum of its parts.</p>, <br/>, <p>To read more, visit <a href="https://2024.igem.wiki/linkoping/">Linkoping</a>, <a href="https://2024.igem.wiki/patras/">Patras</a>, <a href="https://2024.igem.wiki/radboud-university/team">Radboud University</a> and <a href="https://2024.igem.wiki/termosz-selye-hun/">TERMOSZ-Selye-HUN</a>.</p>],
summary: "This collaboration with Linköping and the other iGEM teams was an incredibly enriching experience. Together, we developed a “Delivery-Based Handbook†that will serve as a valuable resource for future teams working with LNPs and liposomes. The knowledge we gained not only enhanced our project but also strengthened our sense of community within iGEM. We are excited to present the handbook at the Grand Jamboree, where we will finally meet our collaborators in person and celebrate the culmination of our collective efforts. This partnership has shown us the immense power of collaboration, and we are proud to have been part of such a meaningful initiative.",
months: "several times",
pictureurl_aim: "https://static.igem.wiki/teams/5247/photos/hp/linkoping-handbook-lnp.webp",
@@ -1378,7 +1369,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>In the process of our interaction with Kai, we learned about the various methods employed in enzyme engineering. He demonstrated the complexity of this field of research and emphasized the importance of choosing the right approach. As a former iGEMer, Kai, inspired by his past experiences, is highly motivated and determined to develop an outstanding project. He pointed out that we cannot rely on classical methods such as directed evolution, but instead should use a rational approach to select mutation candidates. His insights and enthusiasm have encouraged us to think critically and pursue innovative solutions in our work. </p>],
implementation: [<p>We incorporated Kai's insights into our project by shifting our approach to enzyme engineering. By focusing on a more targeted approach, we were able to refine our enzyme optimization process, ensuring that the modifications we made were based on informed, calculated decisions. This not only streamlined our research but also improved the chances of success by reducing the trial-and-error inherent in traditional methods. </p>],
summary: "The team reached out to Kai Schülke, a former iGEM participant and enzyme engineering expert, for guidance on developing a nickase from the endonucleases in use. Kai emphasized the need for a rational, targeted approach rather than traditional methods like directed evolution. His insights helped the team refine their enzyme optimization process, making it more strategic and efficient. This shift reduced trial-and-error efforts and improved the chances of success, driving innovation in their project.",
- months: "July"
+ months: "jul"
},
{
title: "M.Sc.",
@@ -1389,7 +1380,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
pictureurl: pics['nilshefe'],
language: "de",
tag: "Academia",
- heading: "Adapting expression strategies for Fanzor nickases and exploring the potential of Pichia pastoris for SpuFz1 nickase variants ",
+ heading: "Adapting expression strategies for Fanzor nickases and exploring SpuFz1 nickase variants ",
interviewtabid: "nberelsmann",
quote: "Selection for multiple plasmid integrations is the easiest way to optimize protein expression in the yeast strain",
@@ -1399,7 +1390,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>Pichia pastoris (SMD1163) is a promising option for expressing SpuFz1 nickase variants. Refining expression strategies based on expert insights is crucil for success. Nils provided practical tips on yeast expression, including optimizing growth conditions and fine-tuning induction protocols.</p>],
implementation: [<p>We adapted our expression strategy for Fanzor nickases in yeast by incorporating the Pichia pastoris strain (SMD1163) and the provided expression vector into our experiments. Following Nils' detailed protocols and plasmid map, we optimized key steps, enhancing expression efficiency and protein yield.</p>],
summary: "The team sought expert advice from Nils to optimize yeast expression for Fanzor nickases. Nils provided invaluable guidance on addressing potential challenges and troubleshooting the process. He supplied the Pichia pastoris (SMD1163) strain along with a suitable expression vector, crucial for expressing SpuFz1 nickase variants. Additionally, he shared detailed protocols for yeast transformation and growth optimization, enabling the team to replicate his methods effectively for their experiments.",
- months: "July",
+ months: "jul",
},
{
title: "Dr.",
@@ -1409,7 +1400,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
affiliation: "Central Biobank of the University of Bielefeld",
pictureurl: pics['biobank'],
tag: "Academia",
- heading: "Discussed the processes involved in the storage, processing, and security of patient samples.",
+ heading: "Processes involved in the storage, processing, and security of patient samples.",
interviewtabid: "timm",
quoteVorname:"Dr. Timm",
@@ -1449,7 +1440,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What rights do patients have in relation to their samples, and how are these rights safeguarded in your biobank?"
a="Patients have the right to revoke their consent at any time, which can be done at the clinic or biobank. The trustee, acting as an intermediary, will notify BOWL and DIZ to destroy the corresponding samples or data." />
</>,
- months: "august"
+ months: "aug"
},
{
vorname: "'Schüler*innen Akademie'",
@@ -1464,7 +1455,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteNachname: "Lange, Teamm",
quote: "It was wonderful to be part of the Student Academy and to experience how much we learned while teaching. Sharing our knowledge and seeing the students' enthusiasm was incredibly rewarding, even though we couldn't convey everything in just one session.",
summary: [<p>The CeBiTec Student Academy at Bielefeld University provides high school students with hands-on experience in biotechnology and molecular biology, supported by the Osthushenrich Foundation and Detmold district government. iGEM Bielefeld participated by guiding students through a nanopore sequencing experiment, teaching them about lab work, experiment preparation, and safety protocols. The team also presented their iGEM project, PreCyse, giving students insight into real-world research projects and synthetic biology. Many students were excited by the iGEM concept and expressed interest in joining during their future studies. Overall, the academy helped inspire students to explore STEM fields and gain practical scientific skills.</p>],
- months: "August"
+ months: "aug"
},
{
vorname: "Present evidence",
@@ -1504,7 +1495,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</li>
</ul>
],
- months: "august"
+ months: "aug"
},
{
vorname: "Benjamin",
@@ -1562,7 +1553,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Would you be willing to support us in our project? Would you dry our LNPs?" a="The spray dryer requires 5 mL of a solution with 5% solid content. Among these solids, the lipid content can be adjusted between approximately 0.2% and 15%, while the RNA content can range from 0.02% to 1.5%. The remaining percentage is composed of excipients. We’ve published recovery rates of >70%. You can send us the mRNA and LNP components to encapsulate and dry."/>
</>, */
summary: "The conversation focused on spray-drying LNPs, emphasizing the shelf life of RNA-based formulations, optimal storage conditions, and technical requirements for the drying process. Corden Pharma shared insights on the protocol, highlighting the need for testing each LNP formulation individually for stability. AI technology is used to optimize LNP formulations, and potential collaborations were discussed, including support for drying LNPs.",
- months: "august"
+ months: "aug"
},
{
vorname: "Max",
@@ -1583,7 +1574,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
With regard to points five and six, he clarifies that no special hygiene items are required for the stay as long as the toilets are cleaned regularly and there is an additional service for the washbasins. He explains that the sources of danger can be significantly reduced by regular cleaning and the presence of toilet lids, which eliminates the need for special hygiene measures.
He also argues that contactless facilities are not necessary as people wash or sanitise their hands after using the toilet anyway. Finally, he asks whether sources are needed for the hygiene concept and offers his help to create a revised version, which he would then like to review again before it is forwarded to Mr Johannfunke.</p>],
- months: "August"
+ months: "aug"
},
{
title: "Dr.",
@@ -1631,7 +1622,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Thank you so much for your time and insights!" a="You’re welcome! I’m glad I could help." />
</>,
summary: "We identified several crucial insights to guide our project development. Nano-capsules were found to be more stable than nano-complexes, making them our preferred formulation choice. We will utilize chitosan to enhance mRNA stability due to its positive charge, while capsaicin was deemed irrelevant for our purposes. For transfection, we will use OptiMEM as the medium, removing antibiotics 24 hours prior to the procedure. We will assess stability with a Zetasizer and evaluate cytotoxicity using the MTT test. Additionally, we are exploring nasal spray and dry powder formulations to improve nanoparticle delivery. These insights will significantly shape our approach to optimizing mRNA delivery systems.",
- months: "August"
+ months: "aug"
},
{
title: "Dr.",
@@ -1650,7 +1641,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p></p>],
implementation: [<p></p>],
summary: "",
- months: "August",
+ months: "aug",
},
{
vorname: "GxP course",
@@ -1680,7 +1671,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
One of the key speakers during the GXP course was <HPLinktoOtherHPTab tab="gxpexpert" text="Dr. Marcus Berger" />, whose expertise was invaluable to me and the entire team. After the course, I had the opportunity to ask Dr. Berger some questions, further deepening my understanding of the practical applications of GXP in research. The connection with Dr. Berger has been highly beneficial, as his insights helped shape key aspects of our project’s development and compliance with industry standards. His guidance will continue to be a valuable resource for our team moving forward.
Through this training, I feel better positioned to contribute to the team’s efforts, ensuring our project adheres to global safety and ethical guidelines. This experience has strengthened our approach and set a solid foundation for future progress, ensuring that our research, public engagement, and potential clinical applications continue to meet the highest regulatory standards. </p>],
summary: "Kaya, a member of the iGEM Bielefeld 2024 team, completed an intensive one-week GXP (Good Practice) training, which covered Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP). The training provided valuable insights into maintaining high standards of quality, safety, and ethics throughout the research process. Kaya learned crucial skills, such as documenting research processes for reproducibility, creating standard operating procedures (SOPs), and conducting risk assessments using techniques like Failure Mode and Effects Analysis (FMEA). This knowledge is essential for advancing their Cystic Fibrosis gene therapy project toward clinical trials and ensuring compliance with regulatory standards. Dr. Marcus Berger, a key speaker in the course, provided additional guidance, offering valuable insights that will continue to benefit the team.",
- months: "august",
+ months: "aug",
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/gxp/gxp-course-kaya.webp",
pictureurl_interview:"https://static.igem.wiki/teams/5247/photos/for-wiki-texts/gxp/gxp-course-group.webp",
},
@@ -1717,7 +1708,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<b>Broader Perspectives:</b> Leveraged diverse interactions to gain new perspectives that enhanced the project's impact and direction.
</li>
</ul>],
- months: "September"
+ months: "sep"
},
{
title: "",
@@ -1744,7 +1735,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What are the next steps in implementing the hygiene concept?" a="It is essential that the concept be implemented in small, strategic steps. At the same time, it is vital that the rectorate and other decision-makers be consulted on a regular basis to ensure that this matter remains at the forefront of discussions. Furthermore, it is of great importance to engage in political lobbying to secure additional support for this issue." />
</>,
summary: "We got in touch because there was an acute hygiene problem for particularly vulnerable groups like immunocomprised persons at the university. We learnt from the exchange that despite a well-developed hygiene policy, strategic steps are still needed, especially to overcome bureaucratic hurdles. We have integrated these lessons into our project by focusing on continuous collaboration with the Central contact point Barrier-free and other decision-makers.",
- months: "September"
+ months: "sep"
},
{
title: "Dr.",
@@ -1767,7 +1758,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
implementation: [<p>The data were incorporated by confirming that the F508del mutation is not only the most common in Europe but also globally, including in Asia, highlighting a broader perspective and contributing to a significant horizon expansion in understanding the mutation's worldwide prevalence. This finding lends support to the idea that existing therapies targeting the F508del mutation will be effective for many patients worldwide, thereby providing a solid foundation for treatment. As a starting point, this is promising, but future efforts will focus on adapting therapies to address other, rarer mutations found in specific populations.
</p>],
summary: "The contact provided valuable insights into Cystic Fibrosis (CF) in Asia and confirmed that the F508del mutation is the most common, as it is globally. However, the genetic diversity observed in Asia, together with the exacerbation of symptoms by environmental factors such as air pollution, highlights the need for more region-specific research. Future efforts will focus on refining treatments for rarer mutations and improving diagnostic accuracy in Asian populations.",
- months: "September",
+ months: "sep",
interview:<>
<QaBox q="Should we explain our project a little bit in the beginning?" a="That would be great."/>
<QaBox q="Okay. As I wrote to you in the email, we are part of the Bielefeld-CeBiTec item team in Germany this year, and we have a project called Precyse, where we want to develop a platform for next-generation prime editing. With that, we aim to tackle CF mutations, starting with the F508del mutation. The complex should be adaptable for different mutations with minor changes. Essentially, we want to operate like Cas-based projects using prime editing tools but may transition to using a fanzor nickase in the future. Currently, we are working on a delivery system utilizing lipid nanoparticles to transport our complex into the lungs. These nanoparticles will be loaded with mRNA and designed for inhalation, similar to how asthma medications are delivered. Our goal is to advance personalized medicine and improve the standard of living for those affected by the disease, especially since a friend of one of our team members has Cystic Fibrosis and shares insights on the challenges faced by those with the condition." a="That's a very nice summary. I have a couple of clarifying questions. Are you undergraduates?" />
@@ -1798,7 +1789,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
affiliation: "Universität Bielefeld",
pictureurl: pics['kühnel'],
tag: "Academia",
- heading: "Improvement of our culture protocols and experimental outcomes, particularly in maintaining ALI cultures",
+ heading: "Improvement of our culture protocols and experimental outcomes",
interviewtabid: "pkuehnel",
quote: "Connecting with Philipp Kühnel, an expert in nasal cell cultivation, has been invaluable. His insights and expertise in ALI techniques have significantly enhanced our understanding and approach in this crucial area of research.",
@@ -1844,7 +1835,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What are your thoughts on using lipid nanoparticles (LNPs) versus other delivery systems, like AAV vectors?" a="Lipid nanoparticles (LNPs) are a promising delivery system for many genetic therapies, but they have limitations. While LNPs can effectively target certain organs, such as the lungs and liver, they cannot cross the blood-brain barrier and thus unsuitable (for now) to target neuronal pathologies. For these conditions, adeno-associated viral (AAV) vectors may be more effective, as they exhibit an inherent ability to cross the blood-brain barrier. For CF specifically, we have used LNPs to deliver sup-tRNAs directly to the lungs. We teamed up with an US company that develops safe LNPs used also for vaccines. Delivery methods like intratracheal instillation—where the LNPs are introduced into the trachea—allow for targeting the lung tissue more directly, which is critical for treating CF." />
<QaBox q="How do you view prime editing compared to other gene editing technologies?" a="Prime editing is an exciting development in the field of gene editing, but it is important to recognize that no single approach is universally superior. Technologies like prime editing, CRISPR-Cas, and our own tRNA-based therapies each have their strengths and limitations. For instance, prime editing offers a highly precise method for correcting mutations directly at the DNA level, potentially providing a one-time, lifelong cure. However, our approach, which focuses on restoring mRNA translation, does not introduce permanent changes to the genome and unforeseen, also individuum-specific side effects, can be counteracted by immediate termination of the therapy. In turn, it requires continuous re-administration over time. Ultimately, the safety and efficacy of any approach must be carefully weighed. We are not yet at a point where we can definitively rank these technologies because the field is still evolving. Each approach has potential, and the choice of which to use will likely depend on the specific disease and mutation being targeted." />
</>,
- months: "September",
+ months: "sep",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/interview-ignatova/interview-ingatova.webp ",
},
{
@@ -1874,7 +1865,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Additionally, the emphasis on the need for continued advancements in enzyme development and gene therapy has guided us to balance immediate therapeutic benefits with long-term research goals. This ensures that our project addresses both current needs and future possibilities in CF treatment.
By integrating these insights, we aim to ensure our project not only advances scientific understanding but also meets the practical needs of CF patients, ultimately leading to more effective and accessible treatments. </p>],
summary: "The aim of our outreach to Cystic Fibrosis (CF) patients was to gain insights into their daily experiences and how recent treatment advancements have affected their lives. Partnering with MukoDino allowed us to distribute a survey widely, as interviews were limited. Through discussions with patients, we learned about the challenges posed by current treatments, emphasizing the need for therapies that simplify management and reduce physical strain. This feedback has driven our focus on developing more efficient inhalation therapies using spray-dried lipid nanoparticles (LNPs) to deliver gene-editing tools directly to the lungs. We also recognized the global disparities in CF care, motivating us to consider scalability and accessibility for those in resource-limited regions. Patient insights underscored the importance of personalized treatments tailored to individual genetic mutations, prompting us to prioritize enzyme development and gene therapy in our research. Overall, these insights have shaped our project to align closely with the real-world needs of CF patients, aiming for impactful and accessible solutions.",
- months: "September",
+ months: "sep",
interview: <>
<QaBox q="How did you come up with the name ‘Muko-Dino’?" a="The name ‘Muko-Dino’ has a personal history. At a Cystic Fibrosis meeting, another patient joked that I, as a 58-year-old Cystic Fibrosis patient, was a ‘Muko-Dino’. The name alludes to my age, because in the past, Cystic Fibrosis patients had a much shorter life expectancy. So it was unusual for someone with the disease to still be so active at my age. The name stuck - initially as a joke, but I have since adopted it as a kind of nickname." />
<QaBox q="When were you diagnosed with Cystic Fibrosis?" a="I was diagnosed at the age of six after a sweat test. I had lost a lot of weight in the first year of my life and Cystic Fibrosis was already suspected, but it took a while before the diagnosis was actually confirmed." />
@@ -1901,13 +1892,13 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
},
{
title: "Dr. Kerstin Landwehr",
- vorname: "Senior Physician for Pediatrics & Pneumology and",
+ vorname: "and",
nachnname: "Elena Wiesler",
job: "Psychologists in child & adolescent medicine ",
affiliation: "at Bethel Hospital in Bielefeld",
pictureurl: pics['bethel'],
tag: "Medical Professional",
- heading: "Holistic Care for Cystic Fibrosis: Exploring the Psychological Impact and Role of Gene Therapy",
+ heading: "Exploring the Psychological Impact and Role of Gene Therapy",
interviewtabid: "psychol",
language:"de",
@@ -1925,7 +1916,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
implementation: [<p>These findings directly influenced several key areas of the project. We adapted the project to emphasise ease of use and minimal disruption to patients' daily lives. For example, we focused on developing a therapy delivery system that was as non-invasive as possible. Recognising the mental health challenges, we integrated our project with a simple therapeutic method to reduce the mental burden on patients. We have emphasised transparency in communicating the benefits, risks and expectations of gene therapy to ensure that patients have a realistic understanding of the potential outcomes. This includes working closely with patient organisations to disseminate clear and accurate information. We are actively engaging with CF patient communities and healthcare professionals to gather ongoing feedback and ensure that the project evolves based on real patient experiences and challenges. Therefore we used our survey to gather feedback from patients and their families.
By integrating these insights, we aim to create a gene therapy project that addresses not only the medical needs, but also the emotional and practical concerns of CF patients and their families. </p>],
summary: "Our project aims to address the psychological and medical challenges faced by Cystic Fibrosis (CF) patients and their families, particularly regarding gene therapies. We engaged with psychologists and gathered insights from patients and caregivers, revealing significant emotional strain and a mix of optimism and concern about new treatments. Key findings highlighted the importance of psychological support and the practicality of therapies in ensuring patient engagement. In response, we are developing a user-friendly therapy delivery system that minimizes disruption to daily life while emphasizing transparent communication about treatment risks and benefits. Our goal is to create a comprehensive gene therapy solution that meets the medical and emotional needs of CF patients.",
- months: "September",
+ months: "sep",
interview:<>
<QaBox q="Which psychological challenges are particularly relevant for Cystic Fibrosis patients?" a="Psychological problems are often a major issue for Cystic Fibrosis patients. Many patients experience anxiety and depression, and their parents are also often affected. This is exacerbated by the constant strain and stress associated with the disease. Special attention is therefore paid to psychological support during diagnosis and ongoing treatment. Regular screenings for anxiety and depression as well as the early involvement of parents in the treatment process are central components of care."/>
<QaBox q="What significance do the new therapies have for Cystic Fibrosis patients?" a="New therapies are ‘game changers’ for Cystic Fibrosis patients, as they significantly improve life expectancy and quality of life. In the past, Cystic Fibrosis was mainly a paediatric disease with a short life expectancy. Today, new therapies make it possible to significantly extend life expectancy and improve quality of life. Nevertheless, the disease persists, and patients still require comprehensive treatment. Improving quality of life through early and continuous therapy therefore remains of great importance."/>
@@ -1971,7 +1962,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "The interview provided the iGEM team with valuable advice regarding their Prime Editing project and especially on their planned nickase assay. Dr Saito gave detailed feedback on technical challenges, especially with protein expression in E. coli, and suggested switching to yeast for better results. He also encouraged the team to plan carefully, given the project's complexity, and offered guidance on future experiments.  ",
implementation: "We have adapted our planned nickase assay according to Dr Saito's advice and changed it accordingly to expression of the RNP complex using yeast.",
summary: "The interview aimed to gain insights into protein engineering, particularly regarding Fanzor (SpuFz), and to get feedback on potential nickases and a planned nickase assay. Dr. Saito provided valuable advice, suggesting the use of yeast for protein expression over E. coli due to technical challenges and encouraged careful planning. Based on his feedback, the iGEM team has adapted their nickase assay to express the RNP complex in yeast, aligning with Dr. Saito's recommendations.",
- months: "august",
+ months: "aug",
interview:<>
<QaBox q="Are you familiar with iGEM, by the way?" a="Of course, I know it."/>
<QaBox q="Did you participate yourself at some point?" a="Unfortunately, I didn't. I belong to an earlier generation. iGEM actually started relatively recently."/>
@@ -2024,7 +2015,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
These insights clarified the immediate and future steps required to move Precyse forward, particularly in terms of regulatory submissions, quality management, and production scale-up. </p>],
implementation: [<p>We used the insights from the expert to outline the possible next steps for Precyse. This included planning the collection of necessary preclinical data, setting up a GxP-compliant QMS, and preparing for regulatory submission. We also began drafting a strategy for process validation and scaling up production, ensuring that we are aligned with both regulatory and operational requirements. This expert feedback helped us establish a clearer path for the continued development of Precyse. </p>],
summary: "In our consultation with GxP expert Dr. Marcus Berger, we gained key insights to advance the Precyse project, focusing on regulatory strategy, quality management, and clinical development. He emphasized obtaining Scientific Advice from the Paul-Ehrlich-Institut (PEI) and collecting essential preclinical data, including toxicity and biodistribution studies. We also learned how to theoretically set up a GxP-compliant quality management system (QMS) following ICH Q10 guidelines and the importance of critical quality attributes (CQAs) in process validation. Dr. Berger provided guidance on scaling production and following ICH-GCP guidelines for clinical trials, especially for managing risks in gene therapies. This expert advice helped us plan the next steps for Precyse, including preclinical data collection, QMS setup, and production scale-up.",
- months: "September",
+ months: "sep",
interview:<>
<QaBox q="How do we define the regulatory strategy (e.g. IND/IMPD applications)?" a="The regulatory strategy includes the planning of clinical and preclinical development in accordance with applicable regulations, such as CTR 536/2014 in Europe. Planning, conduct, documentation, and reporting applies to clinical trials."/>
<QaBox q="What initial steps are necessary to prepare the submission to the competent authorities?" a="Firstly, a Scientific Advice should be requested from the competent authority. This enables early feedback on the planned development of the substance, which helps to optimise the submission strategy. Scientific advice from authorities such as the Paul Ehrlich Institute ensures that the requirements are correctly understood and implemented. It is also necessary to think about how you want to develop the substance."/>
@@ -2060,7 +2051,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>We employed several analytical techniques, including Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Dynamic Light Scattering (DLS), and zeta potential analysis. TEM and SEM allowed us to visualize the structural morphology of the LNPs, providing detailed images to understand their size and shape on the nanometer scale. DLS was used to measure the size distribution of the particles in solution, while the zeta potential analysis gave us insight into the surface charge, which is crucial for understanding stability in suspension. </p>],
implementation: [<p>Thanks to the guidance and hands-on support of the Physical Chemistry team, we successfully completed these tests, gaining detailed insights into our LNPs that will be crucial for our project's further development. Their expertise not only streamlined the process but also ensured the reliability and accuracy of our results. Here a sneak peak of the results – take a look at the image of our SORT LNP taken via TEM. </p>],
summary: "We collaborated with the Physical Chemistry workgroup to accurately characterize our lipid nanoparticles (LNPs). Their expertise, particularly from Marco, Uwe, and Yvonne, was invaluable in selecting and applying various analytical techniques, including Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Dynamic Light Scattering (DLS), and zeta potential analysis. This collaboration not only enhanced our understanding of the LNPs' size, shape, and stability but also ensured the reliability of our results. With their guidance, we successfully completed our tests, providing crucial insights for the project's advancement.",
- months: "September",
+ months: "sep",
pictureurl_interview: "https://static.igem.wiki/teams/5247/delivery/cryo-em.webp",
pictureurl_implementation: " https://static.igem.wiki/teams/5247/delivery/tem-sort-lnp1.webp",
},
@@ -2082,7 +2073,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>Hakan generously agreed to carry out the transformation and prepare potential positive transformants for cultivation for us, leaving only the purification of the proteins from the supernatant for us to do. </p>],
implementation: [<p>Hakan performed the transformation of a pPIC9K-n3SpuFz1 construct we created into Yeast. Unfortunately, the first attempt of transformation did not yield any positive clones. However, we value his spontaneous and extensive support as a great contribution to our project. </p>],
summary: "We collaborated with the Physical Chemistry workgroup to accurately characterize our lipid nanoparticles (LNPs). Their expertise, particularly from Marco, Uwe, and Yvonne, was invaluable in selecting and applying various analytical techniques, including Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Dynamic Light Scattering (DLS), and zeta potential analysis. This collaboration not only enhanced our understanding of the LNPs' size, shape, and stability but also ensured the reliability of our results. With their guidance, we successfully completed our tests, providing crucial insights for the project's advancement.",
- months: "September",
+ months: "sep",
},
{
title: "M.Sc.",
@@ -2107,7 +2098,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Additionally, Benjamin recommended starting with small-scale tests (about 100 µL) before moving to larger formulations. The ratio of RNA to Chitosan is key to creating negatively charged particles, and a 2:1 ratio should be maintained. We will verify successful encapsulation using microscopic analysis and gel electrophoresis.
This knowledge has directly shaped our approach to using Chitosan. Our focus is now on forming stable RNA-Chitosan complexes, which can be encapsulated in LNPs. We’ve also learned the importance of optimizing concentrations to prevent aggregation or toxicity while ensuring the particles stay within the desired nanometer range. Microscopy and electrophoresis will now be key methods in our protocol to confirm complete RNA encapsulation within the LNPs. </p>],
summary: "In summary, the insights from Benjamin’s expertise were crucial in shaping our understanding of how to integrate Chitosan into our LNP formulations. Chitosan’s protective abilities for RNA, along with its heat stability, make it a valuable component in our project. However, its hydrophilic and cationic nature presents challenges for direct integration into LNP lipid shells, so we are focusing on its use as an encapsulation for the RNA. Benjamin’s advice on concentrations, molecular weight, and complex formation gave us a clear path forward, which will be validated through experimental testing. ",
- months: "september"
+ months: "sep"
},
{
title: "Priv. Doz. Dr. med.",
@@ -2126,7 +2117,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>Through this collaboration with the pathology department, we gained valuable insight into the structural integrity and differentiation of our ALI cultures. HE staining provided detailed information on the overall morphology of the cells, allowing us to assess cellular architecture, tissue organisation and any potential abnormalities. PAS staining provided additional insight by highlighting the presence of polysaccharides and mucosal substances, which are important indicators of tissue differentiation and barrier function in epithelial cultures. This histological analysis confirmed that the cultures had developed the expected cell types and structures, confirming the success of our experimental conditions.</p>],
implementation: [<p>The histological data obtained through the collaboration was instrumental in assessing the quality of our ALI cultures. By confirming that the cultures had developed properly, we were able to refine and optimise our experimental protocol. In particular, the information helped us to validate epithelial differentiation and assess the effectiveness of our culture techniques, and the ability to routinely use FFPE embedding, sectioning and special staining provided us with a robust set of tools for ongoing culture assessment and optimization in future experiments.</p>],
summary: "Collaboration with pathology was key to evaluating and validating ALI cultures, providing essential histological insights that refined protocols and established a reliable method for ongoing culture optimization.",
- months: "october"
+ months: "oct"
},
{
vorname: "Grand Jambooree in Paris",
@@ -2143,7 +2134,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteVorname: "Isabell",
type: "meta",
summary: "As the team gears up for the Grand Jambooree in Paris, our focus has been on finalizing our presentation materials, including a dynamic presentation video that showcases our project and research findings. We are preparing for various formats of engagement, such as presentations and talks, where we’ll share our insights with fellow participants. Additionally, our poster session will provide an opportunity for interactive discussions, and we are bracing for the judging sessions that will critically evaluate our work.",
- months: "october"
+ months: "oct"
},
{
vorname: "Carry It Forward",
@@ -2162,7 +2153,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
summary: [<p>As we move forward with our project, our intention is to continue our research and development at our university.
We believe that by building on our current findings, we can make significant contributions to the field.
Additionally, we are considering reaching out to Mattjis Bulcaen at KU Leuven for potential collaboration in the future, as their expertise could further enhance our work.</p>],
- months: "october"
+ months: "oct"
},
{
vorname: "Homecoming",
@@ -2181,7 +2172,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
summary: [<p>As we move forward with our project, our intention is to continue our research and development at our university.
We believe that by building on our current findings, we can make significant contributions to the field.
Additionally, we are considering reaching out to Mattjis Bulcaen at KU Leuven for potential collaboration in the future, as their expertise could further enhance our work.</p>],
- months: "october"
+ months: "oct"
},
{
vorname: "Carry It Forward",
@@ -2200,7 +2191,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
summary: [<p>As we move forward with our project, our intention is to continue our research and development at our university.
We believe that by building on our current findings, we can make significant contributions to the field.
Additionally, we are considering reaching out to Mattjis Bulcaen at KU Leuven for potential collaboration in the future, as their expertise could further enhance our work.</p>],
- months: "october"
+ months: "oct"
},
]
diff --git a/src/data/parts.ts b/src/data/parts.ts
index d99453a0aeb6bf523c87d39897d0951888d3a56e..53d661c0f20c4b95ccc555d7cb78aebf5ddce60b 100644
--- a/src/data/parts.ts
+++ b/src/data/parts.ts
@@ -78,13 +78,6 @@ export const BasicParts: Array<Part> = [
type: "DNA",
url: "https://parts.igem.org/Part:BBa_K5247107"
},
- {
- partname: " ",
- registrycode: " ",
- description: " ",
- type: " ",
- url: " "
- },
{
partname: "pegRNA_PEAR_01",
registrycode: "BBa_K5247136",
@@ -237,13 +230,6 @@ export const BasicParts: Array<Part> = [
type: "DNA",
url: "https://parts.igem.org/Part:BBa_K5247127"
},
- {
- partname: " ",
- registrycode: " ",
- description: " ",
- type: " ",
- url: ""
- },
{
partname: "PE_CO-mini RT",
registrycode: "BBa_K5247227",
@@ -260,13 +246,6 @@ export const BasicParts: Array<Part> = [
type: "DNA",
url: "https://parts.igem.org/Part:BBa_K5247227"
},
- {
- partname: " ",
- registrycode: " ",
- description: " ",
- type: " ",
- url: " "
- },
{
partname: "PEAR_CFTR",
registrycode: "BBa_K5247135",
diff --git a/src/data/steckbriefe.ts b/src/data/steckbriefe.ts
index 047c60b130eb3a3f9ebab6bc5130f1ec77b99b0e..3dd9757babdabf7f005a9e19ddd957e60a8635f6 100644
--- a/src/data/steckbriefe.ts
+++ b/src/data/steckbriefe.ts
@@ -399,27 +399,25 @@ export const teammembers: Array<SteckbriefInterface> = [
headof: "Wiki",
igemjob: [ "Human Practices", "Public Engagement"],
whyigem: [
- "I am very curious and like projects.",
+ "I am curious and prefer practical learning experiences.",
],
islands: "",
bestpart: [
"Actually seeing results of what you are doing",
],
biggestchallenge: [
- "The biggest challenge is time management. It is quite difficult to manage all the different aspects of the project",
+ "The biggest challenge for me was time and resource management. Not only for myself but especially to ernforce deadlines and distribute tasks for the team.", "I am also not quite sure anymore what my hobbies were before iGEM."
],
funfacts: [
- "My roommates don't let me do experiments in the kitchen anymore",
- "I just have a serious obsession with isopods and efficiency",
- "Doing projects is fun",
+ "Gifted at creating tasteful postcards"
],
- favlabmusic: "Classical crossover, Rock and Baroque Pop",
+ favlabmusic: "Classical crossover, Rock and Baroque Pop - also bagpipe music",
onechange: [
"Make researchers put ALL their data into very detailed databases, that would make looking up data so efficient. You too, faunisticians and anatomists. I'm looking at you"
],
hobbies: [
"Painting & Drawing",
- "Maintaining a website",
+ "Reading",
"Keeping isopods",
],
scientificinterests: "Terrestrial Isopods, Databases, Phylogenetics and Machine Learning",
diff --git a/src/data/symptom-data.tsx b/src/data/symptom-data.tsx
index ed9f70aa36674f6f89ffd17cce42a6568fdfb9fe..b680846e448811455fbb93d0ad3964ddfc52caec 100644
--- a/src/data/symptom-data.tsx
+++ b/src/data/symptom-data.tsx
@@ -45,9 +45,9 @@ export const symptomdata: (Array<SymptomDatensatz>) = [
introduction: [<>Located on the surface of the entire body</>,<>Responsible for barrier function, immunological defense, regulation of homeostasis, sensory functions [25]</>,<>CF affects CFTR channels of sweat glands, which leads to salt deposits on the skin [26]</>,<>This can lead in context of CF to skin irritation (rash or dermatitis) [26]</>,<>Prevention via drinking a lot and a rather salty diet possible [27]</>]
},
{
- name: "Nose",
+ name: "Nasal mucosa and nose",
picture: "https://static.igem.wiki/teams/5247/scientific-figures/nose.svg",
- introduction: [<></>,<>Responsible for smell perception, breathing, filtration and cleaning, and serving as a resonance chamber for the voice [28]</>,<>CF affects thickness of nasal secretions, which cannot drain well [26]</>,<>This can lead in context of CF to nasal congestion, pressure headaches, sinusitis, inflammation of nasal polyps [26]</>,<>Therapy ranges from nasal sprays to surgical removal of nasal polyps [26]</>]
+ introduction: [<>Responsible for smell perception, breathing, filtration and cleaning, and serving as a resonance chamber for the voice [28]</>,<>CF affects thickness of nasal secretions, which cannot drain well [26]</>,<>This can lead in context of CF to nasal congestion, pressure headaches, sinusitis, inflammation of nasal polyps [26]</>,<>Therapy ranges from nasal sprays to surgical removal of nasal polyps [26]</>]
},
{
name: "Brain",
diff --git a/src/pages.ts b/src/pages.ts
index 2271d3973762d6b30c270b185d891eaaf9cb4d11..02036931fdb514432c1026755a80056e5fb696d9 100644
--- a/src/pages.ts
+++ b/src/pages.ts
@@ -5,7 +5,6 @@
Home,
Attributions,
HumanPractices,
- Supplementary,
Parts,
Judging,
ProDesc,
@@ -21,7 +20,7 @@
SafetySidebar
} from "./contents";
import { DescSidebar, NoSidebar, EngSide } from "./contents";
-import { IBIE, JUDGEH, PRODESC, SUPH, PARTH, ENGH, HOMEH, HPH, SPONH, RESH, ATTH, CONTH, DESCH, IMPH, NOTEH, SAFEH, TEAMH } from "./contents";
+import { IBIE, JUDGEH, PRODESC, PARTH, ENGH, HOMEH, HPH, SPONH, RESH, ATTH, CONTH, DESCH, IMPH, NOTEH, SAFEH, TEAMH } from "./contents";
import { Methods } from "./contents/methods";
import { METHH } from "./headers/meth-h";
import { ConSidebar } from "./sidebars/conS";
@@ -212,14 +211,6 @@ const Pages: (Page | Folder)[] = [
header: SAFEH,
navlist: SafetySidebar,
},
- {
- name: "Supplementary Material",
- title: "Supplementary",
- path: "/supplement",
- component: Supplementary,
- header: SUPH,
- navlist: NoSidebar,
- },
{
name: "Roster",
title: "Roster",
@@ -248,7 +239,7 @@ export const NavPages: (Page | PageRef | Folder)[] = [
{
name: "Engineering",
title: "Engineering",
- path: "/engineering"
+ path: "/engineering?tab=tab-our-cycle&scrollTo=ourcycle"
},
{
name: "Materials & Methods",
@@ -258,12 +249,12 @@ export const NavPages: (Page | PageRef | Folder)[] = [
{
name: "Results",
title: "Results",
- path: "/results?scrollTo=experimental-design"
+ path: "/results?scrollTo=abstract"
},
{
name: "Parts",
title: "Parts",
- path: "/parts?scrollTo=Parts Collection2H"
+ path: "/parts?scrollTo=parts-collection"
},
{
name: "Judging",
@@ -319,12 +310,7 @@ export const NavPages: (Page | PageRef | Folder)[] = [
name: "Project Documentation",
title: "Project Documentation",
path: "/project-documentation?scrollTo=our-meeting-protocols",
- },
- {
- name: "Supplementary Material",
- title: "Supplementary",
- path: "/supplement",
- },
+ }
],
},
{
@@ -401,9 +387,9 @@ export const NavPages: (Page | PageRef | Folder)[] = [
path: "/judging?scrollTo=Overview",
},
{
- name: "Best New Basic Part",
+ name: "Best Integrated Human Practice",
title: "Judging",
- path: "/judging?scrollTo=best-new-basic-part",
+ path: "/judging?scrollTo=best-integrated-human-practice",
},
{
name: "Safety & Security",
@@ -411,10 +397,15 @@ export const NavPages: (Page | PageRef | Folder)[] = [
path: "/judging?scrollTo=safety-security",
},
{
- name: "Best Integrated Human Practice",
+ name: "Best New Basic Part",
title: "Judging",
- path: "/judging?scrollTo=best-integrated-human-practice",
- },
+ path: "/judging?scrollTo=best-new-basic-part",
+ },
+ {
+ name: "Judging Session",
+ title: "Judging",
+ path: "/judging?scrollTo=judging-session",
+ },
]
},
{
diff --git a/src/sidebars/jugS.tsx b/src/sidebars/jugS.tsx
index 187f796b68d1de9d3fd2fbd081137354a1ac3b80..ed938286a545a23ce17a0b9d933739b431ee9f4b 100644
--- a/src/sidebars/jugS.tsx
+++ b/src/sidebars/jugS.tsx
@@ -15,5 +15,6 @@ const tabs = [
{tab: "Best Integrated Human Practice"},
{tab: "Safety & Security"},
{tab: "Best New Basic Part"},
- {tab: "Conclusion"}
+ {tab: "Conclusion"},
+ {tab: "Judging Session"}
];
diff --git a/src/sources/entre-sources.tsx b/src/sources/entre-sources.tsx
new file mode 100644
index 0000000000000000000000000000000000000000..ae01ec1c127ba614d12fdc945fbaaabc33788e2a
--- /dev/null
+++ b/src/sources/entre-sources.tsx
@@ -0,0 +1,93 @@
+import BibtexParser from "../components/makeSources";
+
+export default function EntrepreneurSources(){
+ return (
+ <div>
+ <BibtexParser bibtexSources={bibtexSources} special="ent"/>
+ </div>
+ );
+}
+
+
+const bibtexSources = [
+
+ `
+ @article{GMI2021CysticFibrosis,
+
+ title = {Cystic Fibrosis Therapeutics Market Size - By Treatment Method (Medications [Drug Class {CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements}, Route of Administration], Devices), Distribution Channel & Forecast, 2021 - 2027},
+
+ author = {Faizullabhoy, Mariam and Wani, Gauri},
+
+ journal = {GMI Insights},
+
+ year = {2021},
+
+ month = {Sep},
+
+ url = {https://www.gminsights.com/industry-analysis/cystic-fibrosis-therapeutics-market},
+
+ note = {Report ID: GMI5118}
+
+ }
+ `,
+ `
+ @article{Fajac2021,
+
+ title={Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators},
+
+ author={Fajac, Isabelle and Sermet, Isabelle},
+
+ journal={Cells},
+
+ volume={10},
+
+ number={10},
+
+ year={2021},
+
+ month={Oct},
+
+ doi={10.3390/cells10102793},
+
+ url={https://pubmed.ncbi.nlm.nih.gov/34685773/},
+
+ }
+ `,
+ `
+ @misc{ExpertMarketResearch2023,
+
+ title = {Cystic Fibrosis Treatment Market Report and Forecast 2024-2032},
+
+ author = {Rahul Gotadki},
+
+ year = {2023},
+
+ month = {Feb},
+
+ url = {https://www.expertmarketresearch.com/reports/cystic-fibrosis-treatment-market},
+
+ note = {ID: MRFR/Pharma/1293-CR}
+
+ }
+ `,
+ `
+ @misc{DeWeerdt2016,
+
+ author = {Sarah DeWeerdt},
+
+ title = {Developing gene therapy to treat cystic fibrosis: challenges and successes},
+
+ journal = {The Pharmaceutical Journal},
+
+ year = {2016},
+
+ month = {Jun},
+
+ url = {https://pharmaceutical-journal.com/article/feature/developing-gene-therapy-to-treat-cystic-fibrosis-challenges-and-successes},
+
+ note = {Accessed: 30 Sep 2024}
+
+ }
+ `
+
+ ]
\ No newline at end of file
diff --git a/src/sources/res-sources.tsx b/src/sources/res-sources.tsx
new file mode 100644
index 0000000000000000000000000000000000000000..95a191fce658a8aae3112b6384d67682d3cc143b
--- /dev/null
+++ b/src/sources/res-sources.tsx
@@ -0,0 +1,38 @@
+import BibtexParser from "../components/makeSources";
+
+export default function ResultSources(){
+ return (
+ <div>
+ <BibtexParser bibtexSources={bibtexSources} />
+ </div>
+ );
+}
+
+
+const bibtexSources = [
+
+ `
+ @article{wang2023sortlnps,
+ author = {Wang, X. and Liu, S. and Sun, Y. and others},
+ title = {Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery},
+ journal = {Nature Protocols},
+ volume = {18},
+ pages = {265--291},
+ year = {2023},
+ doi = {10.1038/s41596-022-00755-},
+ url = {https://doi.org/10.1038/s41596-022-00755-}
+}
+
+ `,
+ `@article{sousa2024primeediting,
+ author = {Sousa, A. A. and Hemez, C. and Lei, L. and others},
+ title = {Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells},
+ journal = {Nature Biomedical Engineering},
+ year = {2024},
+ doi = {10.1038/s41551-024-01233-3},
+ url = {https://doi.org/10.1038/s41551-024-01233-3}
+}
+`
+
+
+]
\ No newline at end of file
diff --git a/src/utils/useNavigation.ts b/src/utils/useNavigation.ts
index 70b203e72c7ab14e00e02cc316037e7b397d88cc..4e8db67273083e21616ea5d7fbc452896ab2c015 100644
--- a/src/utils/useNavigation.ts
+++ b/src/utils/useNavigation.ts
@@ -104,7 +104,7 @@ export const useNavigation = () => {
console.log("Found scrollToId: " + scrollToId)
paramsAdded = true;
// Wenn bereits Parameter existieren, fügen wir & hinzu, ansonsten ?
- const separator = paramsAdded ? '&' : '?';
+ const separator = paramsAdded ? '?' : '&';
url += `${separator}scrollTo=${scrollToId}`;
}
console.log("Final URL:", url);